WO2013187466A1 - 分岐鎖アルキルヘテロ芳香環誘導体 - Google Patents
分岐鎖アルキルヘテロ芳香環誘導体 Download PDFInfo
- Publication number
- WO2013187466A1 WO2013187466A1 PCT/JP2013/066314 JP2013066314W WO2013187466A1 WO 2013187466 A1 WO2013187466 A1 WO 2013187466A1 JP 2013066314 W JP2013066314 W JP 2013066314W WO 2013187466 A1 WO2013187466 A1 WO 2013187466A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- propan
- triazol
- benzamide
- ethyl
- methyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims abstract description 61
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000019116 sleep disease Diseases 0.000 claims abstract description 7
- 206010019233 Headaches Diseases 0.000 claims abstract description 6
- 208000020685 sleep-wake disease Diseases 0.000 claims abstract description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 5
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 5
- 208000030814 Eating disease Diseases 0.000 claims abstract description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 5
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 5
- 206010020772 Hypertension Diseases 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 208000002193 Pain Diseases 0.000 claims abstract description 5
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 5
- 235000014632 disordered eating Nutrition 0.000 claims abstract description 5
- 206010013663 drug dependence Diseases 0.000 claims abstract description 5
- 230000002124 endocrine Effects 0.000 claims abstract description 5
- 206010015037 epilepsy Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 208000019906 panic disease Diseases 0.000 claims abstract description 5
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 5
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 5
- 208000010643 digestive system disease Diseases 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 374
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 252
- -1 5-fluoropyridin-2-yl Chemical group 0.000 claims description 245
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 109
- 239000000203 mixture Substances 0.000 claims description 57
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 27
- QBRCMHSAOZCHQH-UHFFFAOYSA-N n-pyrimidin-2-ylbenzamide Chemical compound C=1C=CC=CC=1C(=O)NC1=NC=CC=N1 QBRCMHSAOZCHQH-UHFFFAOYSA-N 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- XYDRZYRMVCLDNX-OYKVQYDMSA-N n-[(2s)-1-[4-(4-fluorophenyl)pyrazol-1-yl]propan-2-yl]-n-(2-hydroxypropyl)-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC(O)C)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)N(N=C1)C=C1C1=CC=C(F)C=C1 XYDRZYRMVCLDNX-OYKVQYDMSA-N 0.000 claims description 4
- VPYMEHLEGRGYRR-KRWDZBQOSA-N n-[(2s)-1-[4-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-n-(2-hydroxyethyl)-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CCO)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)N(N=C1)C=C1C1=CC=C(F)C=N1 VPYMEHLEGRGYRR-KRWDZBQOSA-N 0.000 claims description 4
- AUYOEDZTUTZLGZ-AWEZNQCLSA-N n-[(2s)-1-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]propan-2-yl]-n,5-dimethyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(C)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)C(N=1)=NOC=1C1=CC=C(F)C=N1 AUYOEDZTUTZLGZ-AWEZNQCLSA-N 0.000 claims description 4
- UCTMYARPCLQYDJ-KRWDZBQOSA-N n-ethyl-n-[(2s)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)N(N=1)C=CC=1C1=CC=C(F)C=N1 UCTMYARPCLQYDJ-KRWDZBQOSA-N 0.000 claims description 4
- UBPQYWSKDJKHMJ-SFHVURJKSA-N n-ethyl-n-[(2s)-1-[4-(3-methoxyphenyl)triazol-1-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)N(N=N1)C=C1C1=CC=CC(OC)=C1 UBPQYWSKDJKHMJ-SFHVURJKSA-N 0.000 claims description 4
- RJAPASAWWRQAGM-INIZCTEOSA-N n-ethyl-n-[(2s)-1-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)C(O1)=NN=C1C1=CC=C(F)C=C1 RJAPASAWWRQAGM-INIZCTEOSA-N 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- BZXPFBYXSVHIHK-UHFFFAOYSA-N N-(triazol-2-yl)benzamide Chemical compound C(C1=CC=CC=C1)(=O)NN1N=CC=N1 BZXPFBYXSVHIHK-UHFFFAOYSA-N 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 abstract description 19
- 108060005714 orexin Proteins 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 239000002464 receptor antagonist Substances 0.000 abstract description 2
- 229940044551 receptor antagonist Drugs 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 142
- 238000001819 mass spectrum Methods 0.000 description 126
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 124
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 78
- 239000000243 solution Substances 0.000 description 74
- 239000002904 solvent Substances 0.000 description 74
- 239000007858 starting material Substances 0.000 description 72
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 71
- 239000007787 solid Substances 0.000 description 65
- 235000019439 ethyl acetate Nutrition 0.000 description 60
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 58
- 230000002829 reductive effect Effects 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- 239000011734 sodium Substances 0.000 description 34
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 33
- 238000000034 method Methods 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 31
- 239000012044 organic layer Substances 0.000 description 30
- 239000003921 oil Substances 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 26
- 239000012230 colorless oil Substances 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 238000004440 column chromatography Methods 0.000 description 23
- 239000002274 desiccant Substances 0.000 description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 239000012267 brine Substances 0.000 description 18
- 230000014759 maintenance of location Effects 0.000 description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 14
- 238000001816 cooling Methods 0.000 description 14
- 108050000742 Orexin Receptor Proteins 0.000 description 13
- 102000008834 Orexin receptor Human genes 0.000 description 13
- 238000006482 condensation reaction Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 238000005804 alkylation reaction Methods 0.000 description 12
- 239000012046 mixed solvent Substances 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 239000005711 Benzoic acid Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- NLKBUJQLMRHSKP-ZETCQYMHSA-N [(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@H](C)NC(=O)OC(C)(C)C NLKBUJQLMRHSKP-ZETCQYMHSA-N 0.000 description 11
- 235000010233 benzoic acid Nutrition 0.000 description 11
- 239000002994 raw material Substances 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 239000002798 polar solvent Substances 0.000 description 10
- SRBAGFIYKNQXDV-UHFFFAOYSA-N 5-methyl-2-(triazol-2-yl)benzoic acid Chemical compound OC(=O)C1=CC(C)=CC=C1N1N=CC=N1 SRBAGFIYKNQXDV-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 230000003042 antagnostic effect Effects 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 7
- 239000004210 ether based solvent Substances 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- 0 CC*C(*)c1nnc(C)[o]1 Chemical compound CC*C(*)c1nnc(C)[o]1 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- UTENUPFWBIFKPW-UHFFFAOYSA-N 2-(triazol-2-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1N=CC=N1 UTENUPFWBIFKPW-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- XRSBYZYYMKGZQP-LBPRGKRZSA-N n-ethyl-n-[(2s)-1-hydroxypropan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound OC[C@H](C)N(CC)C(=O)C1=CC(C)=CC=C1N1N=CC=N1 XRSBYZYYMKGZQP-LBPRGKRZSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000007958 sleep Effects 0.000 description 5
- QMGGYMSAGNYXTF-NSHDSACASA-N tert-butyl N-[(2S)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]carbamate Chemical compound C[C@@H](Cn1ccc(n1)-c1ccc(F)cn1)NC(=O)OC(C)(C)C QMGGYMSAGNYXTF-NSHDSACASA-N 0.000 description 5
- IEIYKZITHLDELK-JZGIKJSDSA-N (2S)-1-[4-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-amine dihydrochloride Chemical compound Cl.Cl.C[C@H](N)Cn1cc(cn1)-c1ccc(F)cn1 IEIYKZITHLDELK-JZGIKJSDSA-N 0.000 description 4
- ITIPEHBEWGIYQA-VIFPVBQESA-N (2S)-N-ethyl-1-[4-(5-fluoropyridin-2-yl)triazol-1-yl]propan-2-amine Chemical compound CCN[C@@H](C)Cn1cc(nn1)-c1ccc(F)cn1 ITIPEHBEWGIYQA-VIFPVBQESA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DIUMTAGYVCAZRM-ZETCQYMHSA-N tert-butyl n-[(2s)-1-cyanopropan-2-yl]carbamate Chemical compound N#CC[C@H](C)NC(=O)OC(C)(C)C DIUMTAGYVCAZRM-ZETCQYMHSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- FIQXRECUDGCBJZ-JZGIKJSDSA-N (2S)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-amine dihydrochloride Chemical compound Cl.Cl.C[C@H](N)Cn1ccc(n1)-c1ccc(F)cn1 FIQXRECUDGCBJZ-JZGIKJSDSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- ADBMBWBQQBJNNZ-UHFFFAOYSA-N 5-fluoro-2-(1h-pyrazol-5-yl)pyridine Chemical compound N1=CC(F)=CC=C1C1=CC=NN1 ADBMBWBQQBJNNZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000005456 alcohol based solvent Substances 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 3
- 238000006146 oximation reaction Methods 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- COAAFAKCDYEXSX-LBPRGKRZSA-N tert-butyl N-[(2S)-1-[3-(4-fluorophenyl)pyrazol-1-yl]propan-2-yl]carbamate Chemical compound C[C@@H](Cn1ccc(n1)-c1ccc(F)cc1)NC(=O)OC(C)(C)C COAAFAKCDYEXSX-LBPRGKRZSA-N 0.000 description 3
- KYHVIFORPQMMGL-NSHDSACASA-N tert-butyl N-[(2S)-1-[4-(4-fluorophenyl)triazol-1-yl]propan-2-yl]carbamate Chemical compound C[C@@H](Cn1cc(nn1)-c1ccc(F)cc1)NC(=O)OC(C)(C)C KYHVIFORPQMMGL-NSHDSACASA-N 0.000 description 3
- DHBGABWIFZXQIV-JTQLQIEISA-N tert-butyl N-[(2S)-1-[5-(4-fluorophenyl)tetrazol-2-yl]propan-2-yl]carbamate Chemical compound C[C@@H](Cn1nnc(n1)-c1ccc(F)cc1)NC(=O)OC(C)(C)C DHBGABWIFZXQIV-JTQLQIEISA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- LKPAVQRQBMENBF-NVJADKKVSA-N (2S)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]-3-methylbutan-2-amine dihydrochloride Chemical compound Cl.Cl.CC(C)[C@H](N)Cn1ccc(n1)-c1ccc(F)cn1 LKPAVQRQBMENBF-NVJADKKVSA-N 0.000 description 2
- HDHBDIJROVJKEB-XRIOVQLTSA-N (2S)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]butan-2-amine dihydrochloride Chemical compound Cl.Cl.CC[C@H](N)Cn1ccc(n1)-c1ccc(F)cn1 HDHBDIJROVJKEB-XRIOVQLTSA-N 0.000 description 2
- BHLVXALKUQCXRT-QRPNPIFTSA-N (2S)-1-[4-(3,4-difluorophenyl)pyrazol-1-yl]propan-2-amine hydrochloride Chemical compound Cl.C[C@H](N)Cn1cc(cn1)-c1ccc(F)c(F)c1 BHLVXALKUQCXRT-QRPNPIFTSA-N 0.000 description 2
- ICBBVHFXNSOTPK-FVGYRXGTSA-N (2S)-1-[4-(4-fluorophenyl)pyrazol-1-yl]propan-2-amine hydrochloride Chemical compound Cl.C[C@H](N)Cn1cc(cn1)-c1ccc(F)cc1 ICBBVHFXNSOTPK-FVGYRXGTSA-N 0.000 description 2
- ISUADGJIFNUZCD-ZETCQYMHSA-N (2S)-1-[5-(4-fluorophenyl)tetrazol-2-yl]propan-2-amine Chemical compound C[C@H](N)Cn1nnc(n1)-c1ccc(F)cc1 ISUADGJIFNUZCD-ZETCQYMHSA-N 0.000 description 2
- VVRVZXIIKFLHIH-RUCXOUQFSA-N (2S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO.C[C@H](N)CO VVRVZXIIKFLHIH-RUCXOUQFSA-N 0.000 description 2
- GVMORQQUUVGOKM-YFKPBYRVSA-N (2s)-1-(methoxymethoxy)propan-2-amine Chemical compound COCOC[C@H](C)N GVMORQQUUVGOKM-YFKPBYRVSA-N 0.000 description 2
- DOXPYXPDYRVOAG-ZETCQYMHSA-N (2s)-1-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]-n-methylpropan-2-amine Chemical compound CN[C@@H](C)CC1=NOC(C=2N=CC(F)=CC=2)=N1 DOXPYXPDYRVOAG-ZETCQYMHSA-N 0.000 description 2
- SGBGCXQCQVUHNE-YFKPBYRVSA-N (2s)-2-(ethylamino)propan-1-ol Chemical compound CCN[C@@H](C)CO SGBGCXQCQVUHNE-YFKPBYRVSA-N 0.000 description 2
- PTGUFRRCBCNNSY-VIFPVBQESA-N (2s)-n-ethyl-1-[5-(4-fluorophenyl)tetrazol-2-yl]propan-2-amine Chemical compound CCN[C@@H](C)CN1N=NC(C=2C=CC(F)=CC=2)=N1 PTGUFRRCBCNNSY-VIFPVBQESA-N 0.000 description 2
- MJJKTGNMSHXMOT-LBPRGKRZSA-N (3S)-3-[ethyl-[5-methyl-2-(triazol-2-yl)benzoyl]amino]butanoic acid Chemical compound CCN([C@@H](C)CC(O)=O)C(=O)c1cc(C)ccc1-n1nccn1 MJJKTGNMSHXMOT-LBPRGKRZSA-N 0.000 description 2
- FYDZGQJPJKXPMX-ROLXFIACSA-N (4s)-2,4-dimethyl-1,3-oxazolidine Chemical compound C[C@H]1COC(C)N1 FYDZGQJPJKXPMX-ROLXFIACSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- KQFKPRKCARUNAF-UHFFFAOYSA-N 1-(5-fluoropyridin-2-yl)pyrazole-3-carbaldehyde Chemical compound N1=CC(F)=CC=C1N1N=C(C=O)C=C1 KQFKPRKCARUNAF-UHFFFAOYSA-N 0.000 description 2
- UKJOYRRNEBUDAI-UHFFFAOYSA-N 1-(5-fluoropyridin-2-yl)pyrazole-4-carbaldehyde Chemical compound Fc1ccc(nc1)-n1cc(C=O)cn1 UKJOYRRNEBUDAI-UHFFFAOYSA-N 0.000 description 2
- QZWDORUMZZEULE-UHFFFAOYSA-N 1-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]propan-2-amine Chemical compound CC(N)Cc1ccn(n1)-c1ccc(F)cn1 QZWDORUMZZEULE-UHFFFAOYSA-N 0.000 description 2
- WHUNEHVLIYSWNG-UHFFFAOYSA-N 1-[1-(5-fluoropyridin-2-yl)pyrazol-4-yl]propan-2-amine Chemical compound CC(N)Cc1cnn(c1)-c1ccc(F)cn1 WHUNEHVLIYSWNG-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- XFAMUOYNXFXQTC-UHFFFAOYSA-N 2,5-difluoropyridine Chemical compound FC1=CC=C(F)N=C1 XFAMUOYNXFXQTC-UHFFFAOYSA-N 0.000 description 2
- GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 2
- KUVBSDBWMHUTHO-VIFPVBQESA-N 2-[(2S)-1-(methoxymethoxy)propan-2-yl]isoindole-1,3-dione Chemical compound COCOC[C@H](C)N1C(=O)c2ccccc2C1=O KUVBSDBWMHUTHO-VIFPVBQESA-N 0.000 description 2
- KYTIHOIDWMVRKU-ZETCQYMHSA-N 2-[(2s)-1-hydroxypropan-2-yl]isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N([C@H](CO)C)C(=O)C2=C1 KYTIHOIDWMVRKU-ZETCQYMHSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- UODINHBLNPPDPD-UHFFFAOYSA-N 2-bromo-5-fluoropyridine Chemical compound FC1=CC=C(Br)N=C1 UODINHBLNPPDPD-UHFFFAOYSA-N 0.000 description 2
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 2
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- FMRGIEJBUBBULT-UHFFFAOYSA-N 5-fluoro-2-[2-(oxan-2-yl)pyrazol-3-yl]pyridine Chemical compound N1=CC(F)=CC=C1C1=CC=NN1C1OCCCC1 FMRGIEJBUBBULT-UHFFFAOYSA-N 0.000 description 2
- PQNRLVWHOOZNQI-SOFGYWHQSA-N 5-fluoro-2-[3-[(E)-2-nitroprop-1-enyl]pyrazol-1-yl]pyridine Chemical compound n1c(\C=C(/C)[N+]([O-])=O)ccn1-c1ccc(F)cn1 PQNRLVWHOOZNQI-SOFGYWHQSA-N 0.000 description 2
- VCOUQYCDTRYOBV-XBXARRHUSA-N 5-fluoro-2-[4-[(E)-2-nitroprop-1-enyl]pyrazol-1-yl]pyridine Chemical compound c1c(\C=C(/C)[N+]([O-])=O)cnn1-c1ccc(F)cn1 VCOUQYCDTRYOBV-XBXARRHUSA-N 0.000 description 2
- GWFSRJKDYXADOG-UHFFFAOYSA-N 5-fluoro-2-pyrimidin-2-ylbenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1C1=NC=CC=N1 GWFSRJKDYXADOG-UHFFFAOYSA-N 0.000 description 2
- HYMIXLCBOZRYAV-UHFFFAOYSA-N 6-methyl-3-(triazol-2-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C)=CC=C1N1N=CC=N1 HYMIXLCBOZRYAV-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 2
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- RFMJZGYCXUMWAD-LBPRGKRZSA-N N-[(2S)-1-chloropropan-2-yl]-N-ethyl-5-methyl-2-(triazol-2-yl)benzamide Chemical compound CCN([C@@H](C)CCl)C(=O)c1cc(C)ccc1-n1nccn1 RFMJZGYCXUMWAD-LBPRGKRZSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- CTACXYVHMSKGBN-UHFFFAOYSA-N [1-(5-fluoropyridin-2-yl)pyrazol-3-yl]methanol Chemical compound N1=C(CO)C=CN1C1=CC=C(F)C=N1 CTACXYVHMSKGBN-UHFFFAOYSA-N 0.000 description 2
- JPLRXFHEEQSXKM-UHFFFAOYSA-N [1-(5-fluoropyridin-2-yl)pyrazol-4-yl]methanol Chemical compound OCc1cnn(c1)-c1ccc(F)cn1 JPLRXFHEEQSXKM-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- OTSNDKWCXHIIRI-AWEZNQCLSA-N ethyl (3S)-3-[ethyl-[5-methyl-2-(triazol-2-yl)benzoyl]amino]butanoate Chemical compound CCOC(=O)C[C@H](C)N(CC)C(=O)c1cc(C)ccc1-n1nccn1 OTSNDKWCXHIIRI-AWEZNQCLSA-N 0.000 description 2
- OAYFFUSZSXAYGJ-UHFFFAOYSA-N ethyl 1-(5-fluoropyridin-2-yl)pyrazole-3-carboxylate Chemical compound N1=C(C(=O)OCC)C=CN1C1=CC=C(F)C=N1 OAYFFUSZSXAYGJ-UHFFFAOYSA-N 0.000 description 2
- UXFWUVKOSVWXFP-UHFFFAOYSA-N ethyl 1-(5-fluoropyridin-2-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=CC=C(F)C=N1 UXFWUVKOSVWXFP-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 2
- MXWRUJHQROFMPG-NSHDSACASA-N methyl (3s)-3-[[5-methyl-2-(triazol-2-yl)benzoyl]amino]butanoate Chemical compound COC(=O)C[C@H](C)NC(=O)C1=CC(C)=CC=C1N1N=CC=N1 MXWRUJHQROFMPG-NSHDSACASA-N 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- KJLRSUBHSPWFFO-LBPRGKRZSA-N n-[(2s)-1-(methoxymethoxy)propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound COCOC[C@H](C)NC(=O)C1=CC(C)=CC=C1N1N=CC=N1 KJLRSUBHSPWFFO-LBPRGKRZSA-N 0.000 description 2
- 125000004971 nitroalkyl group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- IPISOFJLWYBCAV-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate Chemical compound C1=NN(C(=O)OC(C)(C)C)C=C1B1OC(C)(C)C(C)(C)O1 IPISOFJLWYBCAV-UHFFFAOYSA-N 0.000 description 2
- QMGGYMSAGNYXTF-LLVKDONJSA-N tert-butyl N-[(2R)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]carbamate Chemical compound C[C@H](Cn1ccc(n1)-c1ccc(F)cn1)NC(=O)OC(C)(C)C QMGGYMSAGNYXTF-LLVKDONJSA-N 0.000 description 2
- PDAFIZPRSXHMCO-ZCFIWIBFSA-N tert-butyl n-[(2r)-1-hydroxypropan-2-yl]carbamate Chemical compound OC[C@@H](C)NC(=O)OC(C)(C)C PDAFIZPRSXHMCO-ZCFIWIBFSA-N 0.000 description 2
- YYCIXYPANOZADN-NSHDSACASA-N tert-butyl n-[(2s)-1-[3-(3,4-difluorophenyl)pyrazol-1-yl]propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)CN1C=CC(C=2C=C(F)C(F)=CC=2)=N1 YYCIXYPANOZADN-NSHDSACASA-N 0.000 description 2
- DSPWRFQAAAMRMF-NSHDSACASA-N tert-butyl n-[(2s)-1-[4-(3,4-difluorophenyl)pyrazol-1-yl]propan-2-yl]carbamate Chemical compound C1=NN(C[C@H](C)NC(=O)OC(C)(C)C)C=C1C1=CC=C(F)C(F)=C1 DSPWRFQAAAMRMF-NSHDSACASA-N 0.000 description 2
- ZKOUQNQUBCOJRX-LBPRGKRZSA-N tert-butyl n-[(2s)-1-[4-(4-fluorophenyl)pyrazol-1-yl]propan-2-yl]carbamate Chemical compound C1=NN(C[C@H](C)NC(=O)OC(C)(C)C)C=C1C1=CC=C(F)C=C1 ZKOUQNQUBCOJRX-LBPRGKRZSA-N 0.000 description 2
- UTFDZOFOIGAEMS-NSHDSACASA-N tert-butyl n-[(2s)-1-[4-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]carbamate Chemical compound C1=NN(C[C@H](C)NC(=O)OC(C)(C)C)C=C1C1=CC=C(F)C=N1 UTFDZOFOIGAEMS-NSHDSACASA-N 0.000 description 2
- PDAFIZPRSXHMCO-LURJTMIESA-N tert-butyl n-[(2s)-1-hydroxypropan-2-yl]carbamate Chemical compound OC[C@H](C)NC(=O)OC(C)(C)C PDAFIZPRSXHMCO-LURJTMIESA-N 0.000 description 2
- PRUPLHAKLLHOAN-ZDUSSCGKSA-N tert-butyl n-ethyl-n-[(2s)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N(CC)[C@@H](C)CN1C=CC(C=2N=CC(F)=CC=2)=N1 PRUPLHAKLLHOAN-ZDUSSCGKSA-N 0.000 description 2
- HCOLYNUFEJVLLY-VIFPVBQESA-N tert-butyl-[(2S)-1-[5-(5-fluoropyridin-2-yl)tetrazol-2-yl]propan-2-yl]carbamic acid Chemical compound C[C@@H](Cn1nnc(n1)-c1ccc(F)cn1)N(C(O)=O)C(C)(C)C HCOLYNUFEJVLLY-VIFPVBQESA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- CWQBKZFFXFLREI-YQFADDPSSA-N (2R)-N-ethyl-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-amine dihydrochloride Chemical compound Cl.Cl.CCN[C@H](C)Cn1ccc(n1)-c1ccc(F)cn1 CWQBKZFFXFLREI-YQFADDPSSA-N 0.000 description 1
- KUDVUCOWTDCMRN-FVGYRXGTSA-N (2S)-1-[3-(4-fluorophenyl)pyrazol-1-yl]propan-2-amine hydrochloride Chemical compound Cl.C[C@H](N)Cn1ccc(n1)-c1ccc(F)cc1 KUDVUCOWTDCMRN-FVGYRXGTSA-N 0.000 description 1
- ZQOWLKKKZUQSLN-WWPIYYJJSA-N (2S)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]-N-methylpropan-2-amine dihydrochloride Chemical compound Cl.Cl.CN[C@@H](C)Cn1ccc(n1)-c1ccc(F)cn1 ZQOWLKKKZUQSLN-WWPIYYJJSA-N 0.000 description 1
- CWQBKZFFXFLREI-XRIOVQLTSA-N (2S)-N-ethyl-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-amine dihydrochloride Chemical compound Cl.Cl.CCN[C@@H](C)Cn1ccc(n1)-c1ccc(F)cn1 CWQBKZFFXFLREI-XRIOVQLTSA-N 0.000 description 1
- UIGXPQBTJDTTFV-QMMMGPOBSA-N (2s)-1-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]-n-methylpropan-2-amine Chemical compound CN[C@@H](C)CC1=NOC(C=2C=CC(F)=CC=2)=N1 UIGXPQBTJDTTFV-QMMMGPOBSA-N 0.000 description 1
- GZUYNZHWCKBBDA-JTQLQIEISA-N (2s)-n-ethyl-1-[4-(4-fluorophenyl)triazol-1-yl]propan-2-amine Chemical compound N1=NN(C[C@H](C)NCC)C=C1C1=CC=C(F)C=C1 GZUYNZHWCKBBDA-JTQLQIEISA-N 0.000 description 1
- FOQICOUGVGZCEX-VIFPVBQESA-N (2s)-n-ethyl-1-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]propan-2-amine Chemical compound CCN[C@@H](C)CC1=NOC(C=2C=CC(F)=CC=2)=N1 FOQICOUGVGZCEX-VIFPVBQESA-N 0.000 description 1
- OQEBBZSWEGYTPG-VKHMYHEASA-N (3s)-3-aminobutanoic acid Chemical compound C[C@H](N)CC(O)=O OQEBBZSWEGYTPG-VKHMYHEASA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZZRFDLHBMBHJTI-UHFFFAOYSA-N 1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NN1C1OCCCC1 ZZRFDLHBMBHJTI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- RKWWASUTWAFKHA-UHFFFAOYSA-N 1-bromo-2,3-difluorobenzene Chemical compound FC1=CC=CC(Br)=C1F RKWWASUTWAFKHA-UHFFFAOYSA-N 0.000 description 1
- LFZJRTMTKGYJRS-UHFFFAOYSA-N 1-chloro-4-ethynylbenzene Chemical compound ClC1=CC=C(C#C)C=C1 LFZJRTMTKGYJRS-UHFFFAOYSA-N 0.000 description 1
- XQHAOXRZNLCKJO-UHFFFAOYSA-N 1-ethynyl-4-phenylmethoxybenzene Chemical compound C1=CC(C#C)=CC=C1OCC1=CC=CC=C1 XQHAOXRZNLCKJO-UHFFFAOYSA-N 0.000 description 1
- KQPMYNXRKRUFHX-UHFFFAOYSA-N 1-methoxy-N-(triethylazaniumyl)sulfanylmethanimidate Chemical compound CC[N+](CC)(CC)S[N-]C(=O)OC KQPMYNXRKRUFHX-UHFFFAOYSA-N 0.000 description 1
- JRHPOFJADXHYBR-UHFFFAOYSA-N 1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CNC1CCCCC1NC JRHPOFJADXHYBR-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- RQXIOIGOHVKOEW-UHFFFAOYSA-N 2-(1-bromopropan-2-yloxy)oxane Chemical compound BrCC(C)OC1CCCCO1 RQXIOIGOHVKOEW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- KHCIVRLMGQEZPB-UHFFFAOYSA-N 2-ethynyl-5-fluoropyridine Chemical compound FC1=CC=C(C#C)N=C1 KHCIVRLMGQEZPB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NWDXVJNAXAQTFY-UHFFFAOYSA-N 3-fluoro-2-pyrimidin-2-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1C1=NC=CC=N1 NWDXVJNAXAQTFY-UHFFFAOYSA-N 0.000 description 1
- ZSIUVZFTJKJXLT-UHFFFAOYSA-N 4-(3,4-difluorophenyl)-1h-pyrazole Chemical compound C1=C(F)C(F)=CC=C1C1=CNN=C1 ZSIUVZFTJKJXLT-UHFFFAOYSA-N 0.000 description 1
- ODQIVMKWVSKSKF-UHFFFAOYSA-N 4-(4-fluorophenyl)-1h-pyrazole Chemical compound C1=CC(F)=CC=C1C1=CNN=C1 ODQIVMKWVSKSKF-UHFFFAOYSA-N 0.000 description 1
- GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 description 1
- UIVXXFYJRYVRKJ-UHFFFAOYSA-N 4-fluorobenzohydrazide Chemical compound NNC(=O)C1=CC=C(F)C=C1 UIVXXFYJRYVRKJ-UHFFFAOYSA-N 0.000 description 1
- ABCRUKUNKQYILT-UHFFFAOYSA-N 4-methyl-3-(triazol-2-yl)pyridine-2-carboxylic acid Chemical compound CC1=CC=NC(C(O)=O)=C1N1N=CC=N1 ABCRUKUNKQYILT-UHFFFAOYSA-N 0.000 description 1
- JCDZUGMQQWZARW-UHFFFAOYSA-N 5-(3,4-difluorophenyl)-1h-pyrazole Chemical compound C1=C(F)C(F)=CC=C1C1=CC=NN1 JCDZUGMQQWZARW-UHFFFAOYSA-N 0.000 description 1
- STTNBHIFTZEPSH-UHFFFAOYSA-N 5-(4-fluorophenyl)-1h-pyrazole Chemical compound C1=CC(F)=CC=C1C1=CC=NN1 STTNBHIFTZEPSH-UHFFFAOYSA-N 0.000 description 1
- DTAOERLWDORJFR-UHFFFAOYSA-N 5-(4-fluorophenyl)-2h-tetrazole Chemical compound C1=CC(F)=CC=C1C1=NNN=N1 DTAOERLWDORJFR-UHFFFAOYSA-N 0.000 description 1
- HRNYNCLTFZSMQU-UHFFFAOYSA-N 5-fluoro-2-(1h-pyrazol-4-yl)pyridine Chemical compound N1=CC(F)=CC=C1C1=CNN=C1 HRNYNCLTFZSMQU-UHFFFAOYSA-N 0.000 description 1
- FIZUCGZNDOXNOK-UHFFFAOYSA-N 5-fluoro-2-(2h-tetrazol-5-yl)pyridine Chemical compound N1=CC(F)=CC=C1C1=NNN=N1 FIZUCGZNDOXNOK-UHFFFAOYSA-N 0.000 description 1
- BKWKLESRYKIGNU-HNNXBMFYSA-N 5-fluoro-N-[(2S)-1-[4-(4-fluorophenyl)pyrazol-1-yl]propan-2-yl]-2-pyrimidin-2-ylbenzamide Chemical compound C[C@@H](CN1C=C(C=N1)C1=CC=C(F)C=C1)NC(=O)C1=C(C=CC(F)=C1)C1=NC=CC=N1 BKWKLESRYKIGNU-HNNXBMFYSA-N 0.000 description 1
- BHXHRMVSUUPOLX-UHFFFAOYSA-N 5-fluoropyridine-2-carbonitrile Chemical compound FC1=CC=C(C#N)N=C1 BHXHRMVSUUPOLX-UHFFFAOYSA-N 0.000 description 1
- JTKFIIQGMVKDNZ-UHFFFAOYSA-N 5-fluoropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(F)C=N1 JTKFIIQGMVKDNZ-UHFFFAOYSA-N 0.000 description 1
- LMBXHNCCBIMEOJ-UHFFFAOYSA-N 5-fluoropyridine-2-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=C(F)C=N1 LMBXHNCCBIMEOJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FIYANOHFHXUZNM-UHFFFAOYSA-N CC(C)=NNN=N Chemical compound CC(C)=NNN=N FIYANOHFHXUZNM-UHFFFAOYSA-N 0.000 description 1
- WZPKMDRFYFDHTA-UHFFFAOYSA-P CC(C1)C1(CNC=CC(c(nc1)ccc1F)=[NH2+])NC(c(cc(C)cc1)c1[NH2+]N=CC=N)=O Chemical compound CC(C1)C1(CNC=CC(c(nc1)ccc1F)=[NH2+])NC(c(cc(C)cc1)c1[NH2+]N=CC=N)=O WZPKMDRFYFDHTA-UHFFFAOYSA-P 0.000 description 1
- LPLKEMIOOGBTMQ-BCHBDCPOSA-N CCN(C(c(nc(C)cc1)c1N/N=C\C(C)N)O)C1(C[n]2nnc(-c(nc3)ccc3F)c2)CC1 Chemical compound CCN(C(c(nc(C)cc1)c1N/N=C\C(C)N)O)C1(C[n]2nnc(-c(nc3)ccc3F)c2)CC1 LPLKEMIOOGBTMQ-BCHBDCPOSA-N 0.000 description 1
- XLXWYKQRRDXHFE-UHFFFAOYSA-P CCN(C1(CNC=CC(c(cc2)ncc2F)=N)CC1)C(c(cccc1)c1[NH2+]N=CC=[NH2+])=O Chemical compound CCN(C1(CNC=CC(c(cc2)ncc2F)=N)CC1)C(c(cccc1)c1[NH2+]N=CC=[NH2+])=O XLXWYKQRRDXHFE-UHFFFAOYSA-P 0.000 description 1
- ZEDLRBUXGMWJSY-JRRNRUPGSA-N CCN([C@@H](C)COCOC)C(c(cc(C)cc1)c1N/N=C\C=N)=O Chemical compound CCN([C@@H](C)COCOC)C(c(cc(C)cc1)c1N/N=C\C=N)=O ZEDLRBUXGMWJSY-JRRNRUPGSA-N 0.000 description 1
- JHMZADUBMDWHMG-YERCYKHNSA-N CCOC(C(/C=C\C(c(cc1)ncc1F)=C)=N)=O Chemical compound CCOC(C(/C=C\C(c(cc1)ncc1F)=C)=N)=O JHMZADUBMDWHMG-YERCYKHNSA-N 0.000 description 1
- WKGZFMKIQIVPFA-WFYLSACCSA-O C[C@@H](CN/C=C\C(c(nc1)ccc1F)=[NH2+])N Chemical compound C[C@@H](CN/C=C\C(c(nc1)ccc1F)=[NH2+])N WKGZFMKIQIVPFA-WFYLSACCSA-O 0.000 description 1
- XKVUYEYANWFIJX-UHFFFAOYSA-N Cc1n[nH]cc1 Chemical compound Cc1n[nH]cc1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 1
- NODLZCJDRXTSJO-UHFFFAOYSA-N Cc1n[n](C)cc1 Chemical compound Cc1n[n](C)cc1 NODLZCJDRXTSJO-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101500025902 Homo sapiens Orexin-A Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- MIKVCSYTGYDRTP-OAQYLSRUSA-N N-[(2S)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]-3-methylbutan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound FC=1C=CC(=NC1)C1=NN(C=C1)C[C@H](C(C)C)NC(C1=C(C=CC(=C1)C)N1N=CC=N1)=O MIKVCSYTGYDRTP-OAQYLSRUSA-N 0.000 description 1
- RHPHFYLHFCPMCB-KRWDZBQOSA-N N-[(2S)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]butan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound CC[C@@H](CN1C=CC(=N1)C1=NC=C(F)C=C1)NC(=O)C1=C(C=CC(C)=C1)N1N=CC=N1 RHPHFYLHFCPMCB-KRWDZBQOSA-N 0.000 description 1
- ZJRLBRTXLGBOIP-AWEZNQCLSA-N N-[(2S)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-2-(triazol-2-yl)benzamide Chemical compound C[C@@H](Cn1ccc(n1)-c1ccc(F)cn1)NC(=O)c1ccccc1-n1nccn1 ZJRLBRTXLGBOIP-AWEZNQCLSA-N 0.000 description 1
- DHUXPQFVWPBKMT-HNNXBMFYSA-N N-[(2S)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C[C@@H](CN1C=CC(=N1)C1=NC=C(F)C=C1)NC(=O)C1=C(C=CC(C)=C1)N1N=CC=N1 DHUXPQFVWPBKMT-HNNXBMFYSA-N 0.000 description 1
- GBCFKRCUWZAWAP-AWEZNQCLSA-N N-[(2S)-1-[4-(3,4-difluorophenyl)pyrazol-1-yl]propan-2-yl]-6-methyl-3-(triazol-2-yl)pyridine-2-carboxamide Chemical compound C[C@@H](CN1C=C(C=N1)C1=CC(F)=C(F)C=C1)NC(=O)C1=NC(C)=CC=C1N1N=CC=N1 GBCFKRCUWZAWAP-AWEZNQCLSA-N 0.000 description 1
- YSYFAVLYBIMCES-HNNXBMFYSA-N N-[(2S)-1-[4-(4-fluorophenyl)pyrazol-1-yl]propan-2-yl]-6-methyl-3-(triazol-2-yl)pyridine-2-carboxamide Chemical compound C[C@@H](CN1C=C(C=N1)C1=CC=C(F)C=C1)NC(=O)C1=NC(C)=CC=C1N1N=CC=N1 YSYFAVLYBIMCES-HNNXBMFYSA-N 0.000 description 1
- GBSJXHFWLJSUAG-HNNXBMFYSA-N N-[(2S)-1-[4-(4-fluorophenyl)triazol-1-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C[C@@H](Cn1cc(nn1)-c1ccc(F)cc1)NC(=O)c1cc(C)ccc1-n1nccn1 GBSJXHFWLJSUAG-HNNXBMFYSA-N 0.000 description 1
- NRRQPUHQKYKMEX-AWEZNQCLSA-N N-[(2S)-1-[4-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-2-(triazol-2-yl)benzamide Chemical compound C[C@@H](CN1C=C(C=N1)C1=NC=C(F)C=C1)NC(=O)C1=C(C=CC=C1)N1N=CC=N1 NRRQPUHQKYKMEX-AWEZNQCLSA-N 0.000 description 1
- AFBNEJUAFDQQST-HNNXBMFYSA-N N-[(2S)-1-[4-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C[C@@H](Cn1cc(cn1)-c1ccc(F)cn1)NC(=O)c1cc(C)ccc1-n1nccn1 AFBNEJUAFDQQST-HNNXBMFYSA-N 0.000 description 1
- VTLLIEXRRCXTRX-AWEZNQCLSA-N N-[(2S)-1-[5-(4-fluorophenyl)tetrazol-2-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C[C@@H](Cn1nnc(n1)-c1ccc(F)cc1)NC(=O)c1cc(C)ccc1-n1nccn1 VTLLIEXRRCXTRX-AWEZNQCLSA-N 0.000 description 1
- UBNWXEDGURCFNW-UHFFFAOYSA-N N-[1-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound FC=1C=CC(=NC1)N1N=C(C=C1)CC(C)NC(C1=C(C=CC(=C1)C)N1N=CC=N1)=O UBNWXEDGURCFNW-UHFFFAOYSA-N 0.000 description 1
- CNOPIDMEUXLCKD-UHFFFAOYSA-N N-[1-[1-(5-fluoropyridin-2-yl)pyrazol-4-yl]propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound CC(Cc1cnn(c1)-c1ccc(F)cn1)NC(=O)c1cc(C)ccc1-n1nccn1 CNOPIDMEUXLCKD-UHFFFAOYSA-N 0.000 description 1
- PDUYTJHCVKSZLJ-INIZCTEOSA-N N-ethyl-N-[(2S)-4-[2-(4-fluorobenzoyl)hydrazinyl]-4-oxobutan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound CCN([C@@H](C)CC(=O)NNC(=O)c1ccc(F)cc1)C(=O)c1cc(C)ccc1-n1nccn1 PDUYTJHCVKSZLJ-INIZCTEOSA-N 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100037757 Orexin Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010068932 Terminal insomnia Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- ZDVHQYVXWOYBEH-UHFFFAOYSA-N bis(2-methylpropyl)alumane hexane Chemical compound CCCCCC.[H][Al](CC(C)C)CC(C)C ZDVHQYVXWOYBEH-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- RSSPNKIJFWFVRV-UHFFFAOYSA-N diazomethyl(trimethyl)silane;ethoxyethane Chemical compound CCOCC.C[Si](C)(C)C=[N+]=[N-] RSSPNKIJFWFVRV-UHFFFAOYSA-N 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- UTMQZASUQNNODU-UHFFFAOYSA-N ethanamine;1h-pyrazole Chemical group CCN.C=1C=NNC=1 UTMQZASUQNNODU-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 1
- MSPOSRHJXMILNK-UHFFFAOYSA-N ethyl 1h-pyrazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=NN1 MSPOSRHJXMILNK-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003796 lateral hypothalamic area Anatomy 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
- LTPPVZWUWHGLJK-INIZCTEOSA-N n-ethyl-5-fluoro-n-[(2s)-1-[4-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-2-pyrimidin-2-ylbenzamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=C(F)C=1)C=1N=CC=CN=1)N(N=C1)C=C1C1=CC=C(F)C=N1 LTPPVZWUWHGLJK-INIZCTEOSA-N 0.000 description 1
- YQXUBTNIGRAJCL-AWEZNQCLSA-N n-ethyl-n-[(2s)-1-(methoxymethoxy)propan-2-yl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound COCOC[C@H](C)N(CC)C(=O)C1=CC(C)=CC=C1N1N=CC=N1 YQXUBTNIGRAJCL-AWEZNQCLSA-N 0.000 description 1
- GIIVJJWMFOMHDE-INIZCTEOSA-N n-ethyl-n-[(2s)-1-[3-(5-fluoropyridin-2-yl)pyrazol-1-yl]propan-2-yl]-2-(triazol-2-yl)benzamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=CC=1)N1N=CC=N1)N(N=1)C=CC=1C1=CC=C(F)C=N1 GIIVJJWMFOMHDE-INIZCTEOSA-N 0.000 description 1
- HNNSGEZQVPZHPI-HNNXBMFYSA-N n-ethyl-n-[(2s)-1-[5-(4-fluorophenyl)tetrazol-2-yl]propan-2-yl]-6-methyl-3-(triazol-2-yl)pyridine-2-carboxamide Chemical compound C([C@H](C)N(CC)C(=O)C=1C(=CC=C(C)N=1)N1N=CC=N1)N(N=1)N=NC=1C1=CC=C(F)C=C1 HNNSGEZQVPZHPI-HNNXBMFYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000006137 n-hexyl sulfonyl group Chemical group 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006129 n-pentyl sulfonyl group Chemical group 0.000 description 1
- 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 1
- 230000008452 non REM sleep Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N phthalic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 230000015355 regulation of circadian sleep/wake cycle, sleep Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- ORIHZIZPTZTNCU-YVMONPNESA-N salicylaldoxime Chemical compound O\N=C/C1=CC=CC=C1O ORIHZIZPTZTNCU-YVMONPNESA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LPVDFAPURZWISM-VIFPVBQESA-N tert-butyl n-[(2s)-1-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)CC1=NOC(C=2N=CC(F)=CC=2)=N1 LPVDFAPURZWISM-VIFPVBQESA-N 0.000 description 1
- GDOKWOYJLHTELJ-JTQLQIEISA-N tert-butyl-[(2S)-1-[4-(5-fluoropyridin-2-yl)triazol-1-yl]propan-2-yl]carbamic acid Chemical compound C[C@@H](Cn1cc(nn1)-c1ccc(F)cn1)N(C(O)=O)C(C)(C)C GDOKWOYJLHTELJ-JTQLQIEISA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 210000004515 ventral tegmental area Anatomy 0.000 description 1
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a compound having an orexin (OX) receptor antagonistic action and a pharmaceutically acceptable salt thereof, and sleep disorders, depressions, anxiety disorders, panic disorders, schizophrenia, drug dependence containing them as active ingredients
- OX orexin
- the present invention relates to a therapeutic or prophylactic agent for diseases such as infectious diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorders, headache, migraine, pain, digestive system diseases, epilepsy, inflammation, immune related diseases, endocrine related diseases, and hypertension.
- Orexin is a neuropeptide spliced from preproorexin that is specifically expressed in the lateral hypothalamic area. So far, OX-A consisting of 33 amino acids and OX-B consisting of 28 amino acids have been identified, both of which are deeply involved in the regulation of sleep / wake patterns and the regulation of food intake. .
- OX-A and OX-B act on the OX receptor.
- the OX receptor has been previously cloned into two subtypes of OX1 and OX2 receptors, and both are known to be 7-transmembrane G protein-coupled receptors that are mainly expressed in the brain. .
- the OX1 receptor is specifically conjugated to Gq in the G protein subclass, while the OX2 receptor is conjugated to Gq and Gi / o (see Non-Patent Document 1 and Non-Patent Document 2).
- the tissue distribution varies depending on the subtype of the OX receptor.
- the OX1 receptor is dense in the locus coeruleus, the origin of noradrenergic nerves, and the OX2 receptor in the nodule papillary nucleus, the origin of histamine neurons. (See Non-Patent Document 3, Non-Patent Document 4 and Non-Patent Document 5). Expression of both the OX1 receptor and the OX2 receptor is observed in the raphe nucleus which is the origin nucleus of the serotonin nerve and the ventral tegmental area which is the origin nucleus of the dopamine nerve (see Non-Patent Document 3). The orexin nerve projects to the brain stem and the monoamine nervous system of the hypothalamus and exerts an excitatory effect on those nerves. Furthermore, the expression of OX2 receptor is also seen in the acetylcholine nerve of the brain stem involved in REM sleep control. It also affects the activity of these nerve nuclei (see Non-Patent Document 3 and Non-Patent Document 4).
- Non-patent Documents 6 and 7 When OX-A is administered into the cerebral ventricles of rats, the amount of spontaneous movement is increased (see Non-patent Documents 6 and 7), the normal behavior is enhanced (see Non-Patent Document 7), and the awakening time is extended (non-patent documents). 6).
- the effect of shortening REM sleep time by administration of OX-A is completely antagonized by pretreatment with an OX receptor antagonist (see Non-Patent Document 8).
- Patent Document 1 discloses a pyrazole derivative, but there is no disclosure of a compound having a pyrazole-branched alkylamide skeleton described in the present application.
- OX receptor antagonistic compounds for example, compounds having various structures described in Non-Patent Document 11 are known as reviews, but compounds having a heteroaromatic ring-branched alkylamide skeleton described in the present application are known. There is no disclosure.
- Patent Document 2 discloses a compound having a pyrazole-ethylamide skeleton
- Patent Document 3 discloses a compound having a heteroaromatic ring-branched alkylamide skeleton.
- OX receptor antagonism or a compound having a heteroaromatic ring-branched alkylamide skeleton described in the present application.
- the object of the present invention is to find a novel compound having an OX receptor antagonistic action, sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's chorea, feeding
- the object is to provide a therapeutic or prophylactic agent for diseases such as disorders, headaches, migraines, pain, digestive disorders, epilepsy, inflammation, immune-related diseases, endocrine-related diseases, and hypertension. More specifically, it is to provide a novel compound exhibiting excellent pharmacokinetics and safety as well as excellent OX receptor antagonism.
- the present inventors have demonstrated excellent OX receptor antagonism for certain branched-chain alkylheteroaromatic derivatives represented by the following formulae: As a result, the present invention was completed. Hereinafter, the present invention will be described in detail.
- the embodiment of the present invention (hereinafter referred to as “the compound of the present invention”) is shown below.
- Formula (Ia) (Where X 1 and X 2 are the same or different and represent a nitrogen atom or the formula CH; Y represents any structure of the following formula group (a), R 1 represents a hydrogen atom, a halogen atom, or a C 1-6 alkyl group, R 2 represents a C 1-6 alkyl group (the C 1-6 alkyl group includes a hydroxyl group, a C 1-6 alkoxy group, a C 1-6 alkylsulfonyl group, a diC 1-6 alkylamino group, and a cyano group.
- R 3 represents a triazolyl group or a pyrimidinyl group
- R 4 and R 5 are the same or different and each represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a hydroxyl group, or a C 1-6 alkoxy group
- R 6 represents a C 1-6 alkyl group
- R 1 represents a hydrogen atom, a halogen atom, or a C 1-6 alkyl group
- R 2 represents a C 1-6 alkyl group (the C 1-6 alkyl group may be substituted with one substituent selected from the group consisting of a hydroxyl group and a C 1-6 alkoxy group)
- R 3 represents a triazolyl group or a pyrimidinyl group
- R 4 represents a halogen atom
- R 5 represents a hydrogen atom or a halogen atom
- R 6 represents a C 1-6 alkyl group
- Y is any structure of the following formula group (a1).
- X 1 and X 2 are the same or different and represent a nitrogen atom or the formula CH;
- One of Y 1 and Y 2 represents a nitrogen atom and the other represents CH;
- R 1 represents a hydrogen atom, a halogen atom, or a C 1-6 alkyl group,
- R 2 represents a C 1-6 alkyl group,
- R 3 represents a triazolyl group or a pyrimidinyl group;
- R 4 represents a halogen atom,
- R 5 represents a hydrogen atom or a halogen atom,
- R 6 represents a C 1-6 alkyl group
- a pharmaceutical composition comprising the compound according to any one of (1) to (23) above or a pharmaceutically acceptable salt thereof as an active ingredient.
- the branched alkylheteroaromatic ring derivative of the present invention exhibits affinity for the OX receptor and antagonizes the stimulation of the receptor by a physiological ligand.
- halogen atom is a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
- C 1-6 alkyl group means a linear or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec -Butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-ethylpropyl, n-hexyl, isohexyl, neohexyl group and the like can be mentioned.
- C 1-3 alkyl group means a linear or branched alkyl group having 1 to 3 carbon atoms, and is a methyl, ethyl, n-propyl, or isopropyl group.
- C 1-6 alkoxy group means a linear or branched alkoxy group having 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, Examples thereof include sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, tert-pentyloxy, 1-ethylpropoxy, n-hexyloxy group and the like.
- C 1-6 alkylsulfonyl group means a sulfonyl group substituted with the above “C 1-6 alkyl group”, and includes methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl.
- the “di-C 1-6 alkylamino group” means an amino group having the same or different “C 1-6 alkyl group” as a substituent, and includes dimethylamino, diethylamino, di (n-propyl) ) Amino, di (isopropyl) amino, ethylmethylamino, methyl (n-propyl) amino, methyl (isopropyl) amino and the like.
- insomnia disorder refers to a disorder during sleep onset, the sleep sustaining phase, or awakening, and includes, for example, insomnia.
- insomnia classification include sleep onset disorder, mid-wake awakening, early morning awakening, and deep sleep disorder.
- “pharmaceutically acceptable salt” means a pharmaceutically acceptable acid addition salt, and the acid used includes sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid. Salts with inorganic acids such as acetic acid, benzoic acid, oxalic acid, lactic acid, malic acid, tartaric acid, fumaric acid, maleic acid, citric acid, malonic acid, mandelic acid, gluconic acid, galactaric acid, glucoheptonic acid, glycol And salts with organic acids such as acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, naphthalene-2-sulfonic acid. Conversion from the educt to the salt can be performed by conventional methods.
- Y is preferably a compound having any structure of the following formula group (a1),
- the compound which is the structure in any one of the following formula group (a2) is further more preferable.
- Y is preferably a compound having the structure of the following formula (a3).
- R 1 is preferably a compound that is a hydrogen atom, a fluorine atom, or a methyl group.
- R 2 is preferably a compound which is a methyl group or an ethyl group (the ethyl group may be substituted with one substituent selected from the group consisting of a hydroxyl group and a methoxy group), and a compound which is an ethyl group Further preferred.
- R 3 is preferably a compound which is a 1,2,3-triazol-2-yl group or a pyrimidin-2-yl group.
- R 4 is preferably a compound which is a fluorine atom.
- R 5 is preferably a hydrogen atom or a fluorine atom.
- R 6 is preferably a compound having a C 1-3 alkyl group, and more preferably a compound having a methyl group. Further, a compound in which the configuration at the substitution position of R 6 is the (S) -form is preferable.
- preferred compounds in the compounds of the present invention include N-ethyl-N- ⁇ (2S) -1- [3- (5-fluoropyridin-2-yl) -1H-pyrazol-1-yl] propan-2-yl ⁇ -5-methyl-2- (2H -1,2,3-triazol-2-yl) benzamide, N-ethyl-N- ⁇ (2R) -1- [3- (5-fluoropyridin-2-yl) -1H-pyrazol-1-yl] propan-2-yl ⁇ -5-methyl-2- (2H -1,2,3-triazol-2-yl) benzamide, N-ethyl-N- ⁇ (2S) -1- [3- (4-fluoroph
- the compounds of the present invention include all enantiomers, diastereomers, equilibrium compounds, mixtures of these in any proportion, racemates and the like.
- the compounds according to the present invention also include compounds in which one or more hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atoms and halogen atoms are substituted with radioactive isotopes or stable isotopes. These labeled compounds are useful for metabolic and pharmacokinetic studies, biological ligands, etc. as receptor ligands.
- the compound according to the present invention can be administered orally or parenterally.
- the dosage forms are tablets, capsules, granules, powders, powders, troches, ointments, creams, skin patches, emulsions, suspensions, suppositories, injections, etc., all of which are conventional formulations It can be manufactured by technology (for example, the method prescribed in the 15th revision Japanese Pharmacopoeia). These dosage forms can be appropriately selected according to the patient's symptoms, age, weight, and purpose of treatment.
- These formulations are pharmaceutically acceptable carriers for the compositions containing the compounds of the invention, ie excipients (eg crystalline cellulose, starch, lactose, mannitol), binders (eg hydroxypropylcellulose).
- the compound of the present invention can be orally or parenterally administered to an adult patient at a dosage of 0.001 to 500 mg once or several times a day.
- the dose can be appropriately increased or decreased depending on the type of disease to be treated, the age, weight, symptoms, etc. of the patient.
- a 1 and A 2 represent a halogen atom, a methanesulfonyloxy group, a p-toluenesulfonyloxy group or a trifluoromethanesulfonyloxy group, and other symbols are as defined above.
- Step A-1 The compound (2) can be obtained by converting the hydroxy group of the compound (1) into a general leaving group.
- Examples of the reaction in Step A-1 include chlorination, bromination, iodination, methanesulfonyloxylation, p-toluenesulfonyloxylation and the like.
- chlorination reaction for example, a method in which a leaving group is formed using methanesulfonyl chloride or the like and then substituted with a chlorine atom can be mentioned. Further examples include a method using carbon tetrachloride and triphenylphosphine, a method using thionyl chloride and phosphorus oxychloride.
- a chloride such as sodium chloride or potassium chloride may be added.
- the bromination reaction include a method using carbon tetrabromide and triphenylphosphine.
- Examples of the iodination reaction include a method using iodine, triphenylphosphine, and imidazole.
- the methanesulfonylation and p-toluenesulfonylation of the compound (1) can be carried out using, for example, methanesulfonyl chloride, p-toluenesulfonyl chloride and the like. In these reactions, an appropriate base may be added.
- Examples of the base to be added include organic bases such as triethylamine and diisopropylethylamine, or inorganic bases such as potassium carbonate.
- Examples of the reaction solvent include ether solvents such as tetrahydrofuran, aprotic polar solvents such as N, N-dimethylformamide, halogen solvents such as chloroform, acetonitrile, or a mixed solvent thereof. It can be performed under temperature conditions near the boiling point of the solvent.
- Step A-2 Compound (4) can be obtained by reacting compound (2) with compound (3).
- the reaction in Step A-2 is carried out by using an alcohol solvent such as ethanol, an ether solvent such as tetrahydrofuran, an aprotic polar solvent such as N, N-dimethylformamide, a halogen solvent such as chloroform, dimethyl sulfoxide, acetonitrile, or the like.
- Inorganic solvents such as sodium hydride, sodium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, etc., organic bases such as alkali alkoxides such as sodium ethoxide and potassium tert-butoxide, or lower alkoxides of alkaline earth metals
- organic bases such as alkali alkoxides such as sodium ethoxide and potassium tert-butoxide, or lower alkoxides of alkaline earth metals
- Step A-3 Compound (6) can be obtained by alkylation reaction of compound (4).
- the reaction in Step A-3 can be performed by a general method for alkylating amides.
- the base used in this reaction include inorganic bases such as sodium hydride and sodium hydroxide, and metal lower alkoxides such as sodium ethoxide and tert-butoxypotassium.
- the solvent used in this reaction include ether solvents such as tetrahydrofuran and 1,4-dioxane, aprotic polar solvents such as N, N-dimethylformamide, dimethyl sulfoxide, and acetonitrile, aromatic hydrocarbon solvents such as toluene, and the like. These mixed solvents are mentioned.
- This reaction can be carried out usually at 0 ° C. to 150 ° C., preferably 20 ° C. to 100 ° C.
- Step A-4 Compound (7) is obtained by deprotecting tert-butoxycarbonyl group in the presence of an acid such as hydrochloric acid, sulfuric acid, trifluoroacetic acid, p-toluenesulfonic acid, methanesulfonic acid and the like. be able to.
- an acid such as hydrochloric acid, sulfuric acid, trifluoroacetic acid, p-toluenesulfonic acid, methanesulfonic acid and the like.
- Step A-5 The compound (I) of the present invention can be obtained by a condensation reaction of an amine compound (7) and a carboxylic acid compound (8).
- the reaction in Step A-5 can be carried out by a general amidation method of carboxylic acid and amine. Examples thereof include a method in which a carboxylic acid is led to a carboxylic acid halide such as carboxylic acid chloride or carboxylic acid bromide and then reacted with an amine, and a method in which a carboxylic acid is reacted with an amine in the presence of a dehydrating condensing agent. These reactions can be performed in a solvent in the presence or absence of a base.
- Examples of the halogenating agent used in this reaction include thionyl chloride, oxalyl chloride, phosphorus oxychloride and phosphorus oxybromide.
- Examples of the dehydrating condensing agent used in this reaction include 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide / hydrochloride (EDC / HCl), O- (7-azabenzotriazol-1-yl)- N, N, N ′, N′-tetramethyluronium hexafluorophosphate (HATU), propanephosphonic acid anhydride, dicyclohexylcarbodiimide (DDC), diphenylphosphoryl azide (DPPA), carbonyldiimidazole (CDI), etc.
- DDC dicyclohexylcarbodiimide
- DPPA diphenylphosphoryl azide
- CDI carbonyldiimidazole
- Activating agents such as 1-hydroxybenzotriazole and hydroxysuccinimide can be used as necessary.
- Solvents used in this reaction include ether solvents such as tetrahydrofuran and 1,4-dioxane, aprotic polar solvents such as N, N-dimethylformamide and acetonitrile, halogen solvents such as dichloromethane and chloroform, and toluene.
- An aromatic hydrocarbon solvent, ethyl acetate, or a mixed solvent thereof can be used.
- Examples of the base used in this reaction include organic amines such as pyridine, triethylamine and diisopropylethylamine, and inorganic bases such as potassium carbonate, sodium carbonate and sodium bicarbonate.
- organic amines such as pyridine, triethylamine and diisopropylethylamine
- inorganic bases such as potassium carbonate, sodium carbonate and sodium bicarbonate.
- This invention compound (I) can be manufactured by the method shown to the scheme B as an alternative method.
- Step B-1 The compound (9) can be obtained by deprotecting the tert-butoxycarbonyl group in the presence of an acid.
- the reaction in Step B-1 can be performed according to the same reaction conditions as in Step A-4.
- Step B-2 The compound (10) can be obtained by a condensation reaction of the carboxylic acid compound (8) and the amine compound (9).
- the reaction in Step B-2 can be performed according to the same reaction conditions as in Step A-5.
- Step B-3 The compound (I) of the present invention can be obtained by an alkylation reaction of the compound (10).
- the reaction in Step B-3 can be performed according to the same reaction conditions as in Step A-3.
- Scheme C
- Step C-1 Compound (13) can be obtained by oxadiazole cyclization reaction after amide oximation reaction of compound (11).
- the cyano compound (11) is first converted into an amide oxime by treatment with hydroxylamine or a hydrochloride thereof in an alcohol solvent such as methanol or ethanol, and then tetrahydrofuran, 1,4-dioxane or the like.
- Ether solvents aprotic polar solvents such as N, N-dimethylformamide, halogen solvents such as dichloromethane and chloroform, aromatic hydrocarbon solvents such as toluene, ethyl acetate, acetonitrile, or a mixed solvent thereof
- a dehydrating condensation agent such as carboxylic acid compound (12) and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide / hydrochloride, dicyclohexylcarbodiimide, or carbonyldiimidazole.
- Step C-2 Compound (14) can be obtained by alkylation reaction of Compound (13).
- the reaction in Step C-2 can be carried out according to the same reaction conditions as in Step A-3.
- Step C-3 Compound (15) can be obtained by reacting Compound (14) with an acid.
- the reaction in Step C-3 can be performed according to the same reaction conditions as in Step A-4.
- Step C-4 The compound (Ic) of the present invention can be obtained by a condensation reaction of the compound (15) and the compound (8).
- the reaction in Step C-4 can be performed according to the same reaction conditions as in Step A-5.
- Step D-1 The compound (16) can be obtained by an alkylation reaction of the compound (11). The reaction in Step D-1 can be carried out according to the same reaction conditions as in Step A-3.
- Step D-2 Compound (14) can be obtained by oxadiazole cyclization reaction after amide oximation reaction of compound (16).
- the reaction in Step D-2 can be performed according to the same reaction conditions as in Step C-1.
- Scheme E
- Step E-1 Compound (18) can be obtained by reacting compound (2) with compound (17).
- the reaction in Step E-1 can be performed according to the same reaction conditions as in Step A-2.
- Step E-2 Compound (19) can be obtained by reacting Compound (18) with an acid.
- the reaction in Step E-2 can be performed according to the same reaction conditions as in Step A-4.
- Step E-3 The compound (20) can be obtained by a condensation reaction of the compound (19) and the compound (8).
- the reaction in Step E-3 can be performed according to the same reaction conditions as in Step A-5.
- Step E-4 The compound (Ie) of the present invention can be obtained by an alkylation reaction of the compound (20).
- the reaction in step E-1 can be carried out according to the same reaction conditions as in step A-3.
- Scheme F
- Step F-1 Compound (21) can be obtained by alkylation reaction of compound (18).
- the reaction in step F-1 can be carried out according to the same reaction conditions as in step A-3.
- Step F-2 Compound (22) can be obtained by reacting Compound (21) with an acid.
- the reaction in Step F-2 can be performed according to the same reaction conditions as in Step A-4.
- Step F-3 The compound (Ie) of the present invention can be obtained by a condensation reaction of the compound (22) and the compound (8).
- the reaction in Step F-3 can be performed according to the same reaction conditions as in Step A-5.
- Scheme G
- Step G-1 Compound (25) can be obtained by 1,3-dipolar cycloaddition reaction of compound (23) and compound (24).
- the reaction in Step G-1 can be carried out by a method of treating with a copper catalyst in the presence of a reducing agent.
- a reducing agent used in this reaction include (L) -ascorbic acid and sodium ascorbate.
- the copper catalyst used in this reaction include copper sulfate, copper iodide, copper bromide, and copper chloride.
- a base is required, and triethylamine, diisopropylethylamine, or the like can be used.
- Solvents used in this reaction include alcohol solvents such as methanol and ethanol, ether solvents such as tetrahydrofuran and 1,4-dioxane, aprotic polar solvents such as N, N-dimethylformamide, dimethyl sulfoxide and acetonitrile, toluene
- An aromatic hydrocarbon solvent such as water, water or a mixed solvent thereof. This reaction can be carried out usually at 0 ° C. to 150 ° C., preferably 25 ° C. to 100 ° C.
- Step G-2 The compound (26) can be obtained by reacting the compound (25) with an acid.
- the reaction in Step G-2 can be performed according to the same reaction conditions as in Step A-4.
- Step G-3 The compound (27) can be obtained by a condensation reaction of the compound (26) and the compound (8).
- the reaction in Step G-3 can be performed according to the same reaction conditions as in Step A-5.
- Step G-4 The compound (Ig) of the present invention can be obtained by an alkylation reaction of the compound (27).
- the reaction in Step G-4 can be carried out according to the same reaction conditions as in Step A-3.
- the compound of the present invention represented by the formula (Ih) can be produced by the method shown in Scheme H.
- Step H-1 The compound (30) can be obtained by a coupling reaction of the compound (28) and the compound (29).
- the reaction in Step H-1 can be carried out by a general method in which an aromatic ring is substituted with a nitrogen atom of an azole compound using a catalyst and a ligand in the presence of a base.
- a catalyst used in this reaction include copper catalysts such as copper (0), copper (I) iodide, copper (I) chloride, and copper (I) oxide.
- the ligand used in this reaction include N, N′-dimethylethylenediamine, N, N′-dimethylcyclohexane-1,2-diamine, 2-aminopyridine, 1,10-phenanthroline, 2-hydroxybenzaldehyde oxime, and the like.
- Examples of the base used in this reaction include potassium carbonate, potassium phosphate, potassium hydroxide, tert-butoxypotassium, cesium carbonate, sodium carbonate, sodium bicarbonate, sodium acetate, sodium methoxide, tetrabutylammonium hydroxide and the like. .
- Solvents used in this reaction include alcohol solvents such as methanol and ethanol, ether solvents such as tetrahydrofuran and 1,4-dioxane, aprotic polar solvents such as N, N-dimethylformamide, dimethyl sulfoxide and acetonitrile, dichloromethane , Halogen solvents such as chloroform, aromatic hydrocarbon solvents such as toluene, water, or a mixed solvent thereof.
- This reaction can be carried out usually at 0 ° C. to 150 ° C., preferably 25 ° C. to 100 ° C.
- Step H-2 The compound (31) can be obtained by the reduction reaction of the ester of the compound (30).
- the reaction in Step H-2 is carried out by using an alcohol solvent such as methanol or ethanol, an ether solvent such as tetrahydrofuran or 1,4-dioxane, an aromatic hydrocarbon solvent such as toluene, or a mixed solvent thereof, lithium aluminum hydride,
- the reaction can be carried out under conditions for reaction with a reducing agent such as diisobutylaluminum hydride, sodium borohydride, lithium borohydride and the like. This reaction can be carried out at ⁇ 80 ° C. to 150 ° C., preferably 0 ° C. to 25 ° C.
- Step H-3 The compound (32) can be obtained by an oxidation reaction of the hydroxyl group of the compound (31).
- the reaction in Step H-3 is carried out by using a halogen-based solvent such as dichloromethane or chloroform, dimethyl sulfoxide or acetonitrile, a desvalent reagent, a hypervalent iodine compound such as 2-iodoxybenzoic acid, pyridinium chlorochromate, pyridinium dichromate, or the like.
- the reaction can be carried out under the condition of reacting with an oxidizing agent such as chromate, tetrapropylammonium perruthenate, manganese dioxide. This reaction can be carried out at 0 ° C. to 150 ° C., preferably 25 ° C. to 80 ° C.
- Step H-4 The compound (33) can be obtained by a condensation reaction of the compound (32) and a nitroalkane (R 6 —CH 2 —NO 2 ).
- the reaction in Step H-4 is carried out in a halogen solvent such as chloroform, an ether solvent such as tetrahydrofuran and 1,4-dioxane, an alcohol solvent such as methanol and ethanol, an aprotic solvent such as dimethylformamide, or without solvent.
- a halogen solvent such as chloroform
- an ether solvent such as tetrahydrofuran and 1,4-dioxane
- an alcohol solvent such as methanol and ethanol
- an aprotic solvent such as dimethylformamide
- reaction In the presence of an organic base such as triethylamine, diisopropylethylamine, and ethanolamine, or an inorganic base such as sodium hydroxide, the reaction can be carried out under the condition of reacting with nitroalkane (R 6 —CH 2 —NO 2 ). This reaction can be carried out at 0 ° C. to 50 ° C.
- organic base such as triethylamine, diisopropylethylamine, and ethanolamine
- inorganic base such as sodium hydroxide
- Step H-5 Compound (34) can be obtained by the reduction reaction of the double bond and nitro group of compound (33).
- the reaction in Step H-5 is conducted in a hydrogen atmosphere in the presence of a metal catalyst such as palladium or platinum in an alcohol solvent such as methanol or ethanol, an ether solvent such as tetrahydrofuran or 1,4-dioxane, ethyl acetate or a mixed solvent thereof.
- a metal catalyst such as palladium or platinum
- an alcohol solvent such as methanol or ethanol
- an ether solvent such as tetrahydrofuran or 1,4-dioxane, ethyl acetate or a mixed solvent thereof.
- This reaction can be carried out at 25 ° C to 80 ° C.
- the reaction can be performed under the same reaction conditions as in Step H-2.
- Step H-6 The compound (35) can be obtained by a condensation reaction of the compound (34) and the compound (8).
- the reaction in Step H-6 can be performed according to the same reaction conditions as in Step A-5.
- Step H-7 The compound (Ih) of the present invention can be obtained by an alkylation reaction of the compound (35).
- the reaction in Step H-7 can be carried out according to the same reaction conditions as in Step A-3.
- Step I-1 The compound (37) can be obtained by a condensation reaction of the compound (36) and the compound (8).
- the reaction in Step I-1 can be carried out according to the same reaction conditions as in Step A-5.
- Step I-2 Compound (38) can be obtained by alkylation reaction of compound (37).
- the reaction in Step I-2 can be carried out according to the same reaction conditions as in Step A-3.
- Step I-3 Compound (39) can be obtained by hydrolysis reaction of Compound (38).
- the reaction in step I-3 is described in J. Am. F. W. OMcOmie, Protective Groups Organic Chemistry. W. Greene and P.M. G. M. It can be carried out under the reaction conditions described in Wuts, Protective Groups In Organic Synthesis.
- the method etc. which hydrolyze using mineral acids, such as hydrochloric acid and a sulfuric acid, or inorganic bases, such as sodium hydroxide and potassium hydroxide, etc. are mentioned.
- Examples of the solvent used in this reaction include alcohol solvents such as methanol and ethanol, ether solvents such as tetrahydrofuran and 1,4-dioxane, water, and mixed solvents thereof. This reaction can be carried out at 0 ° C. to 100 ° C.
- Step I-4 Compound (41) can be obtained by condensation reaction of Compound (39) and Compound (40). The reaction in Step I-4 can be carried out according to the same reaction conditions as in Step A-5.
- Step I-5 The compound (Ii) of the present invention can be obtained by dehydration cyclization reaction of the compound (41).
- the reaction in Step I-5 is carried out in an aprotic polar solvent such as tetrahydrofuran, 1,4-dioxane or the like, N, N-dimethylformamide, acetonitrile or a mixed solvent thereof, phosphorus oxychloride, sulfuric acid, Burgess reagent. It can carry out on the conditions made to react with dehydrating agents, such as. This reaction can be carried out at 25 ° C to 100 ° C.
- the compound of the present invention represented by the formula (Ig) can be produced by the method shown in Scheme J.
- Step J-1 The compound (42) can be obtained by an alkylation reaction of the compound (25).
- the reaction in Step J-1 can be carried out according to the same reaction conditions as in Step A-3.
- Step J-2 The compound (43) can be obtained by reacting the compound (42) with an acid.
- the reaction in Step J-2 can be performed according to the same reaction conditions as in Step A-4.
- Step J-3 The compound (Ig) of the present invention can be obtained by a condensation reaction of the compound (43) and the compound (8).
- the reaction in Step J-3 can be performed according to the same reaction conditions as in Step A-5.
- Scheme K
- Step K-1 The compound (45) can be obtained by a condensation reaction of the compound (44) and the compound (8).
- the reaction in Step K-1 can be carried out according to the same reaction conditions as in Step A-5.
- Step K-2 The compound (46) can be obtained by an alkylation reaction of the compound (45).
- the reaction in step K-2 can be carried out according to the same reaction conditions as in step A-3.
- Step K-3 The compound (47) can be obtained by removing the protecting group for the hydroxy group of the compound (46).
- a comprehensive overview of the reaction in step K-3 can be found in F. W. OMcOmie, Protective Groupsin Organic Chemistry. W. Greene and P.M. G. M. Wuts, Protective Groups in Organic Synthesis.
- Pr of the compound (46) is an acetal protecting group such as a methoxymethyl group
- the compound (47) can be obtained by reacting with an acid such as hydrochloric acid.
- Step K-4 The compound (48) can be obtained by converting the hydroxy group of the compound (47) into a general leaving group.
- the reaction in Step K-4 can be performed according to the same reaction conditions as in Step A-1.
- Step K-5 Compound (49) can be obtained by replacing the leaving group of compound (48) with an azide ion.
- an aprotic polar solvent such as N, N-dimethylformamide or dimethyl sulfoxide, water, tetrahydrofuran or a mixed solvent thereof can be used as a solvent.
- the reaction temperature can be about 0 ° C. to the boiling point of the reaction solvent, but preferably 50 ° C. to 80 ° C.
- Step K-6 The compound (Ig) of the present invention can be obtained by 1,3-dipolar cycloaddition reaction of the compound (49) and the compound (24).
- the reaction in Step K-6 can be performed according to the same reaction conditions as in Step G-1.
- Step L-1 Compound (50) can be obtained by substituting the leaving group of Compound (48) with an inorganic cyanide.
- the reaction in Step L-1 can be carried out by using sodium cyanide or potassium cyanide in an aprotic polar solvent such as N, N-dimethylformamide, an alcohol such as MeOH, water, tetrahydrofuran, or a mixed solvent thereof.
- the reaction is carried out at about room temperature to about the boiling point of the reaction solvent, preferably 50 ° C to 100 ° C.
- Step L-2 Compound (Ic) of the present invention can be obtained by oxadiazole cyclization reaction after amide oximation reaction of compound (50).
- the reaction in Step L-2 can be performed according to the same reaction conditions as in Step C-1.
- Scheme M
- Step M-1 The compound (47) can be obtained by a condensation reaction of the compound (51) and the compound (8).
- the reaction in Step M-1 can be carried out according to the same reaction conditions as in Step A-5.
- Step N-1 Compound (52) can be obtained by protecting the hydroxy group of Compound (1).
- a comprehensive overview of the reaction in Step N-1 can be found in F. W. McOmie, Protective Groups in Organic Chemistry. W. Greene and P.A. G. M. Wuts, Protective Groups in Organic Synthesis.
- the protecting group of the compound (52) is an acyl protecting group such as benzoyl group
- an acyl halide such as benzoyl chloride, benzoic anhydride, acetic anhydride or the like is reacted with an organic base such as pyridine or triethylamine.
- an organic base such as pyridine or triethylamine.
- Step N-2 The compound (53) can be obtained by an alkylation reaction of the compound (52).
- the reaction in Step N-2 can be carried out according to the same reaction conditions as in Step A-3.
- Step N-3 The compound (54) can be obtained by reacting the compound (53) with an acid.
- the reaction in Step N-3 can be performed according to the same reaction conditions as in Step A-4.
- Step N-4 The compound (55) can be obtained by the condensation reaction of the compound (54) and the compound (8).
- the reaction in Step N-4 can be performed according to the same reaction conditions as in Step A-5.
- Step N-5 Compound (47) can be obtained by removing the protecting group for the hydroxy group of compound (55).
- a comprehensive overview of the reaction in step N-5 can be found in F. W. OMcOmie, Protective Groupsin Organic Chemistry. W. Greene and P.M. G. M. Wuts, Protective Groups in Organic Synthesis.
- Pr of the compound (55) is an acyl protecting group such as a benzoyl group
- the compound (47) can be obtained by reacting the compound (55) with a base such as potassium hydroxide or sodium hydroxide.
- KP-Sil when purified using column chromatography is Biotage's SNAPPartridge KP-Sil, “HP-Sil” is Biotage ’s SNAPPartrige HP-Sil, “SNAP Ultra”. ”For Biotage SNAPartridge SNAP Ultra,“ KP-NH ”for Biotage SNAPPartridge KP-NH,“ Grace ”for Grace Revelis Silica Flash Cartridge,“ GraceNH ”for GraceNH .
- Biotage's ISOLUTE Phase Separator was used for “ISOLUTE Phase Separator” in the post-processing operations of the following Reference Examples and Examples.
- LCMS liquid chromatography mass spectrum
- MS measuring instrument Shimadzu LCMS-2010EV or MicroMass Platform LC
- compound names were named by ACD / Name (ACD / Labs 12.01, Advanced Chemistry Development Inc.).
- 1,1 -′- carbonyldiimidazole (0.96 g, 5.94 mmol) was added to DMF (10 mL) of 5-fluoropyridine-2-carboxylic acid hydrochloride (0.97 g, 5.45 mmol), and 1 at room temperature. Stir for hours. A DMF (3 mL) solution of the residue obtained above was added to the reaction solution, heated to 90 ° C., stirred for 7 hours, and then stirred at room temperature for 60 hours. Water was added to the reaction mixture and extracted with EtOAc.
- Reference Examples 82 to 86 were obtained in the same manner as Reference Example 81.
- Table 1 shows the structural formula, compound name, and MS data of the obtained compound.
- Examples 2 to 17 were obtained in the same manner as in Example 1.
- the structural formulas, compound names, and LCMS data of the obtained compounds are shown in Tables 2-1 and 2-2.
- Examples 19 to 33 were obtained in the same manner as in Example 18.
- the structural formulas, compound names, and LCMS data of the obtained compounds are shown in Tables 3-1 and 3-2.
- Examples 35 to 40 were obtained in the same manner as in Example 34.
- Table 4 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Examples 42 to 44 were obtained in the same manner as in Example 41.
- Table 5 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Examples 46 to 61 were obtained in the same manner as in Example 45.
- the structural formulas, compound names, and LCMS data of the obtained compounds are shown in Tables 6-1 to 6-3.
- Example 47-2 N-ethyl-N- ⁇ (2S) -1- [5- (5-fluoropyridin-2-yl) -1,2,4-oxadiazol-3-yl] propane-2- Yl ⁇ -5-methyl-2- (2H-1,2,3-triazol-2-yl) benzamide
- the title compound can also be obtained as follows.
- Example 63 was obtained in the same manner as in Example 62.
- Table 7 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Examples 66 to 70 were obtained in the same manner as in Example 65.
- Table 8 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Example 72 was obtained in the same manner as in Example 71.
- Table 9 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Example 75 was obtained in the same manner as in Example 74.
- Table 10 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Examples 78 to 84 were obtained in the same manner as in Example 77.
- Table 11 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Examples 86 to 88 were obtained in the same manner as in Example 85.
- Table 12 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Examples 89 to 91 were obtained in the same manner as in Example 71.
- Table 13 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Examples 93 to 99 were obtained in the same manner as in Example 92.
- Table 14 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Test example (measurement of orexin antagonistic activity)
- the antagonistic activity of test compounds against human orexin type 1 receptor (hOX1R) and orexin type 2 receptor (hOX2R) is described in the literature (Toshikatsu Okumura et al., Biochemical and Biophysical Research Communications, 280, 976-981, 2001). The method was modified. Chinese hamster ovary (CHO) cells in which hOX1R and hOX2R are forcibly expressed were seeded in each well of a 96-well Black clear bottom plate (Nunc) at 20,000 cells, 0.1 mM MEM non-essential amino acids, 0.
- CHO Chinese hamster ovary
- the cells were cultured in Ham's F-12 medium (Invitrogen) containing 5 mg / mL G418, 10% fetal calf serum for 16 hours under conditions of 37 ° C. and 5% CO 2 .
- an assay buffer containing 25 ⁇ M Fluo-4AM ester (Dojin) 25 mM HEPES (Dojin), Hanks' balanced salt solution (Invitrogen), 0.1% bovine serum albumin, 2.5 mM probenecid, 100 ⁇ L of 200 ⁇ g / mL Amaranth (above Sigma-Aldrich), pH 7.4
- the test compound was dissolved in dimethyl sulfoxide to 10 mM, diluted with assay buffer, 150 ⁇ L was added, and the mixture was incubated for 30 minutes.
- Peptide substituted with 2 amino acids of human orexin-A ligand (Pyr-Pro-Leu-Pro-Asp-Ala-Cys-Arg-Gln-Lys-Thr-Ala-Ser-Cys-Arg-Leu-Tyr-Glu -Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 (Peptide Institute) is a final concentration of 300 pM for hOX1R and hOX2R Each was diluted with an assay buffer so as to be 3 nM, and 50 ⁇ L of this ligand solution was added to initiate the reaction.
- the fluorescence value of each well was measured for 3 minutes every second using a Functional Drug Screening System (FDSS; manufactured by Hamamatsu Photonics), and the antagonistic activity was determined using the maximum fluorescence value as an indicator of intracellular Ca 2+ concentration.
- the antagonistic activity of the test compound was calculated by setting the fluorescence value of the well to which only the dilution buffer was added to 100% and the fluorescence value of the well to which the buffer solution containing no ligand and compound was added to 0%.
- the 50% inhibitory concentration (IC 50 value) was determined from the fluorescence value upon addition.
- the IC 50 values of the compounds of the present invention are shown in Table 15.
- the compound of the present invention was shown to have an OX receptor antagonistic action. Therefore, the compound of the present invention or a pharmaceutically acceptable salt thereof is a disease modulated by OX receptor antagonism, such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease , Parkinson's disease, Huntington's disease, eating disorders, headache, migraine, pain, digestive disorders, epilepsy, inflammation, immune related diseases, endocrine related diseases, hypertension, etc. .
- OX receptor antagonism such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease , Parkinson's disease, Huntington's disease, eating disorders, headache, migraine, pain, digestive disorders, epilepsy, inflammation, immune related diseases, endocrine related diseases, hypertension, etc.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
OX受容体のサブタイプによって組織分布は異なっており、OX1受容体はノルアドレナリン作動性神経の起始核である青斑核、OX2受容体はヒスタミン神経の起始核である結節乳頭核に高密度に発現している(非特許文献3、非特許文献4及び非特許文献5参照)。セロトニン神経の起始核である縫線核や、ドパミン神経の起始核である腹側被蓋野にはOX1受容体とOX2受容体両方の発現がみられる(非特許文献3参照)。オレキシン神経は脳幹と視床下部のモノアミン神経系に投射し、それらの神経に対して興奮性の影響を与えており、さらにREM睡眠の制御に関わる脳幹のアセチルコリン神経にもOX2受容体の発現がみられ、これらの神経核の活性にも影響を及ぼしている(非特許文献3及び非特許文献4参照)。
OX受容体拮抗作用化合物として、特許文献1にはピラゾール誘導体が開示されているが、本願記載のピラゾール-分岐鎖アルキルアミド骨格を有する化合物についての開示はない。また、OX受容体拮抗作用化合物としては、例えば総説として非特許文献11に記載の種々の構造を有する化合物が知られているが、本願記載のヘテロ芳香環-分岐鎖アルキルアミド骨格を有する化合物についての開示はない。一方、特許文献2にはピラゾール-エチルアミド骨格を有する化合物が、また、特許文献3にはヘテロ芳香環-分岐鎖アルキルアミド骨格を有する化合物が開示されているが、特許文献2及び特許文献3にはOX受容体拮抗作用に関する開示や本願記載のヘテロ芳香環-分岐鎖アルキルアミド骨格を有する化合物の開示はない。
以下、本発明を詳細に説明する。本発明の態様(以下、「本発明化合物」という)は以下に示すものである。
(1)
式(Ia)
X1及びX2は、同一に又は異なって窒素原子、又は式CHを示し、
Yは下記式群(a)のいずれかの構造を示し、
R2は、C1-6アルキル基(該C1-6アルキル基は、水酸基、C1-6アルコキシ基、C1-6アルキルスルホニル基、ジC1-6アルキルアミノ基、及びシアノ基からなる群より選ばれる1個の置換基で置換されてもよい)を示し、
R3は、トリアゾリル基、又はピリミジニル基を示し、
R4及びR5は、同一又は異なって水素原子、ハロゲン原子、C1-6アルキル基、水酸基、又はC1-6アルコキシ基を示し、
R6は、C1-6アルキル基を示す)
で表される化合物、又はその医薬上許容される塩。
(2)式(Ia)
R2は、C1-6アルキル基(該C1-6アルキル基は、水酸基及びC1-6アルコキシ基からなる群より選ばれる1個の置換基で置換されてもよい)を示し、
R3は、トリアゾリル基、又はピリミジニル基を示し、
R4は、ハロゲン原子を示し、
R5は、水素原子、又はハロゲン原子を示し、
R6は、C1-6アルキル基を示す)
で表される化合物、又はその医薬上許容される塩。
(3)上記式(Ia)において、
Yが下記式群(a1)のいずれかの構造である(1)又は(2)に記載の化合物、又はその医薬上許容される塩。
R1が、水素原子、フッ素原子、又はメチル基である(1)~(3)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(5)上記式(Ia)において、
R2が、メチル基、又はエチル基(該エチル基は、水酸基及びメトキシ基からなる群より選ばれる1個の置換基で置換されてもよい)である(1)~(4)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(6)上記式(Ia)において、
R4が、フッ素原子である(1)~(5)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(7)上記式(Ia)において、
R5が、水素原子、又はフッ素原子である(1)~(6)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(8)上記式(Ia)において、
R6が、C1-3アルキル基である(1)~(7)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(9)上記式(Ia)において、
Yが下記式群(a2)のいずれかの構造である(1)~(8)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
R2が、エチル基である(1)~(10)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(12)上記式(Ia)において、
R6が、メチル基である(1)~(11)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(13)上記式(Ia)が、式(IIa)
X1及びX2は、同一に又は異なって窒素原子、又は式CHを示し、
Y1及びY2は、いずれか一方が窒素原子、他方がCHを示し、
R1は、水素原子、ハロゲン原子、又はC1-6アルキル基を示し、
R2は、C1-6アルキル基を示し、
R3は、トリアゾリル基、又はピリミジニル基を示し、
R4は、ハロゲン原子を示し、
R5は、水素原子、又はハロゲン原子を示し、
R6は、C1-6アルキル基を示す)
で表される化合物、又はその医薬上許容される塩。
(16)上記式(I)において、
R1が、水素原子、フッ素原子、又はメチル基である(15)に記載の化合物、又はその医薬上許容される塩。
(17)上記式(I)において、
R2が、メチル基、又はエチル基である(15)又は(16)いずれかに記載の化合物、又はその医薬上許容される塩。
(18)上記式(I)において、
R4が、フッ素原子である(15)~(17)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(19)上記式(I)において、
R5が、水素原子、又はフッ素原子である(15)~(18)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(20)上記式(I)において、
R6が、C1-3アルキル基である(15)~(19)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(21)上記式(I)において、
R6が、メチル基である(15)~(20)のいずれか1つに記載の化合物、又はその医薬上許容される塩。
(22)上記式(I)が、式(II)
(23)上記(1)に記載される下記化合物群及びその医薬上許容される塩から選ばれるいずれか1種又は2種以上の混合物。
N-エチル-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2R)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
5-フルオロ-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,5-ジメチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-2-フルオロ-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-(ピリミジン-2-イル)ベンズアミド、
N-エチル-4-フルオロ-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-メチル-3-(ピリミジン-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[3-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[3-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-5-フルオロ-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]ブタン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,6-ジメチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,6-ジメチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-5-フルオロ-2-(ピリミジン-2-イル)ベンズアミド、
5-フルオロ-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-フルオロ-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
5-クロロ-N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-6-メチル-3-(ピリミジン-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-6-メチル-3-(ピリミジン-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{1-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-4-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{1-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,3,4-オキサジアゾール-2-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-[2-(ジメチルアミノ)エチル]-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-N-[2-(メチルスルホニル)エチル]-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-クロロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-N-エチル-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(3-ヒドロキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-メチル-N-{(2S)-1-[4-(ピリジン-2-イル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-メチル-N-[(2S)-1-(4-フェニル-1H-1,2,3-トリアゾール-1-イル)プロパン-2-イル]-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-メチル-N-{(2S)-1-[4-(3-メチルフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(3-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロ-3-メトキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-ヒドロキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(3-メトキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシプロピル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド。
(24)上記(1)~(23)いずれか1つに記載の化合物、又はその医薬上許容される塩を有効成分として含有する医薬組成物。
(25)上記(1)~(23)いずれか1つに記載の化合物、又はその医薬上許容される塩を有効成分として含有する睡眠障害、うつ病、不安障害、パニック障害、統合失調症、薬物依存症、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、摂食障害、頭痛、片頭痛、疼痛、消化器疾患、てんかん、炎症、免疫関連疾患、内分泌関連疾患、又は高血圧の疾患の治療又は予防薬。
「ハロゲン原子」とは、フッ素原子、塩素原子、臭素原子、ヨウ素原子である。
「C1-6アルキル基」とは、直鎖状又は分岐鎖状の炭素数1~6個のアルキル基を意味し、例えばメチル、エチル、n-プロピル、イソプロピル、n-ブチル、イソブチル、sec-ブチル、tert-ブチル、n-ペンチル、イソペンチル、ネオペンチル、tert-ペンチル、1-エチルプロピル、n-ヘキシル、イソヘキシル、ネオヘキシル基等を挙げることができる。
「C1-3アルキル基」とは、直鎖状又は分岐鎖状の炭素数1~3個のアルキル基を意味し、メチル、エチル、n-プロピル、及びイソプロピル基である。
「C1-6アルコキシ基」とは、直鎖状又は分岐鎖状の炭素数1~6個のアルコキシ基を意味し、例えばメトキシ、エトキシ、n-プロポキシ、イソプロポキシ、n-ブトキシ、イソブトキシ、sec-ブトキシ、tert-ブトキシ、n-ペンチルオキシ、イソペンチルオキシ、ネオペンチルオキシ、tert-ペンチルオキシ、1-エチルプロポキシ、n-ヘキシルオキシ基等を挙げることができる。
「C1-6アルキルスルホニル基」とは、前記の「C1-6アルキル基」で置換されたスルホニル基を意味し、メチルスルホニル、エチルスルホニル、n-プロピルスルホニル、イソプロピルスルホニル、n-ブチルスルホニル、イソブチルスルホニル、sec-ブチルスルホニル、tert-ブチルスルホニル、n-ペンチルスルホニル、イソペンチルスルホニル、ネオペンチルスルホニル、tert-ペンチルスルホニル、n-ヘキシルスルホニル等の基を挙げることができる。
「ジC1-6アルキルアミノ基」とは、前記の「C1-6アルキル基」を置換基として同一又は異なって2個有するアミノ基を意味し、ジメチルアミノ、ジエチルアミノ、ジ(n-プロピル)アミノ、ジ(イソプロピル)アミノ、エチルメチルアミノ、メチル(n-プロピル)アミノ、メチル(イソプロピル)アミノ等の基を挙げることができる。
Yは、下記式群(a1)のいずれかの構造である化合物が好ましく、
R2は、メチル基、又はエチル基(該エチル基は、水酸基及びメトキシ基からなる群より選ばれる1個の置換基で置換されてもよい)である化合物が好ましく、エチル基である化合物がさらに好ましい。
R3は、1,2,3-トリアゾール-2-イル基、又はピリミジン-2-イル基である化合物が好ましい。
R4は、フッ素原子である化合物が好ましい。
R5は、水素原子又はフッ素原子である化合物が好ましい。
R6は、C1-3アルキル基である化合物が好ましく、メチル基である化合物がより好ましい。また、R6の置換位置の立体配置は(S)-体である化合物が好ましい。
本発明化合物中の好ましい化合物の例として、
N-エチル-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2R)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
5-フルオロ-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,5-ジメチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-2-フルオロ-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-(ピリミジン-2-イル)ベンズアミド、
N-エチル-4-フルオロ-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-メチル-3-(ピリミジン-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[3-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[3-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-5-フルオロ-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]ブタン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,6-ジメチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,6-ジメチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-5-フルオロ-2-(ピリミジン-2-イル)ベンズアミド、
5-フルオロ-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-フルオロ-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
5-クロロ-N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-6-メチル-3-(ピリミジン-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-6-メチル-3-(ピリミジン-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{1-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-4-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{1-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,3,4-オキサジアゾール-2-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-[2-(ジメチルアミノ)エチル]-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-N-[2-(メチルスルホニル)エチル]-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-クロロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-N-エチル-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(3-ヒドロキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-メチル-N-{(2S)-1-[4-(ピリジン-2-イル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-メチル-N-[(2S)-1-(4-フェニル-1H-1,2,3-トリアゾール-1-イル)プロパン-2-イル]-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-メチル-N-{(2S)-1-[4-(3-メチルフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(3-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロ-3-メトキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-ヒドロキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(3-メトキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシプロピル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
又はその医薬上許容される塩が挙げられる。
なお、本発明化合物が水和物又は溶媒和物を形成する場合、それらも本発明の範囲内に含まれる。同様に、本発明化合物の水和物又は溶媒和物の医薬上許容される塩も本発明の範囲内に含まれる。
本発明に係る化合物には、一つ以上の水素原子、炭素原子、窒素原子、酸素原子、ハロゲン原子が放射性同位元素や安定同位元素と置換された化合物も含まれる。これらの標識化合物は、代謝や薬物動態研究、受容体のリガンド等として生物学的分析等に有用である。
本発明に係る化合物は、経口又は非経口的に投与することができる。その投与剤型は錠剤、カプセル剤、顆粒剤、散剤、粉剤、トローチ剤、軟膏剤、クリーム剤、皮膚貼付剤、乳剤、懸濁剤、坐剤、注射剤等であり、いずれも慣用の製剤技術(例えば、第15改正日本薬局方に規定する方法等)によって製造することができる。これらの投与剤型は、患者の症状、年齢、体重、及び治療の目的に応じて適宜選択することができる。
これらの製剤は、本発明の化合物を含有する組成物に薬理学的に許容されるキャリヤー、すなわち、賦形剤(例えば、結晶セルロース、デンプン、乳糖、マンニトール)、結合剤(例えば、ヒドロキシプロピルセルロース、ポリビニルピロリドン)、滑沢剤(例えば、ステアリン酸マグネシウム、タルク)、崩壊剤(例えば、カルボキシメチルセルロースカルシウム)、その他薬理学的に許容される各種添加剤を配合し、製造することができる。
本発明の化合物は、成人患者に対して1回の投与量として0.001~500mgを1日1回又は数回に分けて経口又は非経口で投与することが可能である。なお、この投与量は治療対象となる疾病の種類、患者の年齢、体重、症状等により適宜増減することができる。
スキームA
スキームB
本発明化合物(I)は、別法としてスキームBに示す方法で製造することができる。
スキームC
式(I-c)で表される本発明化合物は、スキームCに示す方法で製造することができる。
スキームD
中間体(14)は、スキームDに示す方法でも製造することができる。
工程D-1:化合物(16)は、化合物(11)のアルキル化反応により得ることができる。工程D-1における反応は、工程A-3と同様の反応条件に従って実施できる。
スキームE
式(I-e)で表される本発明化合物は、スキームEに示す方法で製造することができる。
工程E-1:化合物(18)は、化合物(2)と化合物(17)を反応させることにより得ることができる。工程E-1における反応は、工程A-2と同様の反応条件に従って行うことができる。
スキームF
スキームG
スキームH
式(I-h)で表される本発明化合物は、スキームHに示す方法で製造することができる。
工程H-1:化合物(30)は、化合物(28)と化合物(29)のカップリング反応により得ることができる。工程H-1における反応は塩基の存在下、触媒及びリガンドを用いてアゾール化合物の窒素原子への芳香環置換を行う一般的方法により実施できる。例えば、Synlett, 2003, 15, 2428-2439.に記載の方法又はそれに準じた方法が挙げられる。本反応で用いられる触媒としては、銅(0)、ヨウ化銅(I)、塩化銅(I)、酸化銅(I)等の銅触媒が挙げられる。本反応で用いられるリガンドとしては、N,N’-ジメチルエチレンジアミン、N,N’-ジメチルシクロヘキサン-1,2-ジアミン、2-アミノピリジン、1,10-フェナンスロリン、2-ヒドロキシベンズアルデヒドオキシム等が挙げられる。本反応で用いられる塩基としては炭酸カリウム、リン酸カリウム、水酸化カリウム、tert-ブトキシカリウム、炭酸セシウム、炭酸ナトリウム、炭酸水素ナトリウム、酢酸ナトリウム、ナトリウムメトキシド、テトラブチルアンモニウムヒドロキシド等が挙げられる。本反応で用いられる溶媒としてはメタノール、エタノール等のアルコール系溶媒、テトラヒドロフランや1,4-ジオキサン等のエーテル系溶媒、N,N-ジメチルホルムアミド、ジメチルスルホキシド、アセトニトリル等の非プロトン性極性溶媒、ジクロロメタン、クロロホルム等のハロゲン系溶媒、トルエン等の芳香族炭化水素系溶媒、水又はそれらの混合溶媒が挙げられる。本反応は通常0℃~150℃、好ましくは25℃~100℃で行うことができる。
スキームI
式(I-i)で表される本発明化合物は、スキームIに示す方法で製造することができる。
工程I-1:化合物(37)は化合物(36)と化合物(8)の縮合反応により得ることができる。工程I-1における反応は工程A-5と同様の反応条件に従って行うことができる。
スキームJ
式(I-g)で表される本発明化合物は、スキームJに示す方法で製造することができる。
工程J-1:化合物(42)は、化合物(25)のアルキル化反応により得ることができる。工程J-1における反応は、工程A-3と同様の反応条件に従って実施できる。
スキームK
式(I-g)で表される本発明化合物は、スキームKに示す方法で製造することができる。
工程K-1:化合物(45)は化合物(44)と化合物(8)の縮合反応により得ることができる。工程K-1における反応は工程A-5と同様の反応条件に従って行うことができる。
スキームL
式(I‐c)で表される本発明化合物は、スキームLに示す方法で製造することができる。
工程L-1:化合物(50)は化合物(48)の脱離基を無機シアン化物で置換することにより得られる。工程L-1における反応は、N,N-ジメチルホルムアミド等の非プロトン性極性溶媒やMeOH等のアルコール、水、テトラヒドロフラン、もしくはこれらの混合溶媒中でシアン化ナトリウムやシアン化カリウムを用いることで実施できる。反応温度は室温付近~反応溶媒の沸点付近、好ましくは50℃~100℃で実施する。
スキームM
中間体(47)は、スキームMに示す方法でも製造することができる。
工程M-1:化合物(47)は化合物(51)と化合物(8)の縮合反応により得ることができる。工程M-1における反応は工程A-5と同様の反応条件に従って行うことができる。
スキームN
中間体(47)は、スキームNに示す方法でも製造することができる。
工程N-1:化合物(52)は化合物(1)のヒドロキシ基を保護することにより得られる。工程N-1における反応に関する包括的概観は、J. F. W. McOmie 著、Protective Groupsin Organic Chemistry.、及びT. W. Greene 及びP.G.M.Wuts著、Protective Groups in Organic Synthesis.に見出され得る。例えば、化合物(52)の保護基がベンゾイル基等のアシル系保護基である場合、塩化ベンゾイル等のハロゲン化アシルや安息香酸無水物、無水酢酸等をピリジンやトリエチルアミン等の有機塩基とともに反応させることにより得ることができる。
機械:Gilson社 preparative HPLC system
カラム:資生堂 Capcelpak C18 MGII 5μm 20×150mm
溶媒:A液;0.1%トリフルオロ酢酸含有水、B液;0.1%トリフルオロ酢酸含有アセトニトリル
グラジエント:0分(A液/B液=90/10)、22分(A液/B液=20/80)、25分(A液/B液=10/90)
流速:20mL/min、検出法:UV 254nm
条件1
測定機械:MicroMass社 Platform LCおよびAgilent社 Agilent1100
カラム:Waters社 SunFire C18 2.5μm4.6x50mm
溶媒:0.1%トリフルオロ酢酸含有水、B液;0.1%トリフルオロ酢酸含有アセトニトリル
グラジエント:0分(A液/B液=90/10)、0.5分(A液/B液=90/10)、5.5分(A液/B液=20/80)、6.0分(A液/B液=1/99)、6.3分(A液/B液=1/99)
流速:1mL/min、検出法:254nm
イオン化法:エレクトロンスプレー法(ESI:Electron Spray Ionization)
条件2
測定機械:Agilent社 Agilent2900及びAgilent6150
カラム:Waters社 Acquity CSH C18 1.7μm 2.1x50mm
溶媒:A液;0.1%ギ酸含有水、B液;0.1%ギ酸含有アセトニトリル
グラジエント:0分(A液/B液=80/20)、1.2~1.4分(A液/B液=1/99)
流速:0.8mL/min、検出法:UV 254nm
イオン化法:エレクトロンスプレー法(ESI:Electron Spray Ionization)
MS測定機器:島津社LCMS-2010EVあるいはMicroMass社 Platform LC
以下の参考例および実施例において、化合物名はACD/Name (ACD/Labs 12.01, Advanced Chemistry Development Inc.)により命名した。
MgSO4(硫酸マグネシウム)、Na2SO4(無水硫酸ナトリウム)、Na2CO3(炭酸ナトリウム)、Cs2CO3(炭酸セシウム)、KOH(水酸化カリウム)、NaHCO3(炭酸水素ナトリウム)、NaOH(水酸化ナトリウム)、NH4Cl(塩化アンモニウム)、DMF(N,N-ジメチルホルムアミド)、EtOAc(酢酸エチル)、CHCl3(クロロホルム)、THF(テトラヒドロフラン)、Et2O(ジエチルエーテル)、MeOH(メタノール)、EtOH(エタノール)、H2O(水)、HATU[O-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロホスファート]、Pd(PPh3)4[テトラキストリフェニルホスフィンパラジウム(0)]、Pd/C(パラジウム炭素)、brine(飽和食塩水)、Boc(tert-ブトキシカルボニル)、Ms(メタンスルホニル)、DIPEA(N,N-ジイソプロピルエチルアミン)、MeI(ヨウ化メチル)、EtI(ヨウ化エチル)、CuI(ヨウ化銅(I))、NaH(水素化ナトリウム)、LAH(LiAlH4、水素化アルミニウムリチウム)、NaBH4(水素化ホウ素ナトリウム)、HCl(塩化水素)。
MS (ESI pos.) m/z : 248 [M+H]+
MS (ESI pos.) m/z : 164 [M+H]+
MS (ESI pos.) m/z : 164 [M+H]+
MS (ESI neg.) m/z : 179 [M-H]-
MS (ESI pos.) m/z : 276 [M+Na]+
MS (ESI pos.) m/z : 321 [M+H]+
MS (ESI pos.) m/z : 349 [M+H]+
MS (ESI pos.) m/z : 249 [M+H]+
MS (ESI pos.) m/z : 221 [M+H]+
MS (ESI pos.) m/z : 392 [M+H]+
MS (ESI pos.) m/z : 406 [M+H]+
MS (ESI pos.) m/z : 321 [M+H]+
MS (ESI pos.) m/z : 221 [M+H]+
MS (ESI pos.) m/z : 392 [M+H]+
MS (ESI pos.) m/z : 406 [M+H]+
MS (ESI pos.) m/z : 321 [M+H]+
MS (ESI pos.) m/z : 349 [M+H]+
MS (ESI pos.) m/z : 249 [M+H]+
MS (ESI pos.) m/z : 349 [M+H]+
MS (ESI pos.) m/z : 249 [M+H]+
MS (ESI pos.) m/z : 434 [M+H]+
MS (ESI pos.) m/z : 335 [M+H]+
MS (ESI pos.) m/z : 235 [M+H]+
MS (ESI pos.) m/z : 420 [M+H]+
MS (ESI pos.) m/z : 320 [M+H]+
MS (ESI pos.) m/z : 348 [M+H]+
MS (ESI pos.) m/z : 248 [M+H]+
MS (ESI pos.) m/z : 335 [M+H]+
MS (ESI pos.) m/z : 235 [M+H]+
MS (ESI pos.) m/z : 320 [M+H]+
MS (ESI pos.) m/z : 348 [M+H]+
MS (ESI pos.) m/z : 248 [M+H]+
MS (ESI pos.) m/z : 338 [M+H]+
MS (ESI pos.) m/z : 366 [M+H]+
MS (ESI pos.) m/z : 266 [M+H]+
MS (ESI pos.) m/z : 320 [M+H]+
MS (ESI pos.) m/z : 220 [M+H]+
MS (ESI pos.) m/z : 406 [M+H]+
MS (ESI pos.) m/z : 338 [M+H]+
MS (ESI pos.) m/z : 238 [M+H]+
MS (ESI pos.) m/z : 424 [M+H]+
MS (ESI pos.) m/z : 420 [M+H]+
MS (ESI pos.) m/z : 460 [M+Na]+
MS (ESI pos.) m/z : 207 [M+Na]+
MS (ESI pos.) m/z : 345 [M+Na]+
MS (ESI pos.) m/z : 359 [M+Na]+
MS (ESI pos.) m/z : 237 [M+H]+
MS (ESI pos.) m/z : 373 [M+Na]+
MS (ESI pos.) m/z : 251 [M+H]+
MS (ESI pos.) m/z : 213 [M+H]+
MS (ESI pos.) m/z : 372 [M+Na]+
MS (ESI pos.) m/z : 250 [M+H]+
MS (ESI pos.) m/z : 221 [M+Na]+
MS (ESI pos.) m/z : 358 [M+Na]+
MS (ESI pos.) m/z : 236 [M+H]+
MS (ESI pos.) m/z : 258 [M+Na]+
MS (ESI pos.) m/z : 216 [M+Na]+
MS (ESI pos.) m/z : 192 [M+H]+
MS (ESI pos.) m/z : 249 [M+H]+
MS (ESI pos.) m/z : 221 [M+H]+
MS (ESI pos.) m/z : 406 [M+H]+
MS (ESI pos.) m/z : 236 [M+H]+
MS (ESI pos.) m/z : 194 [M+H]+
MS (ESI pos.) m/z : 192 [M+H]+
MS (ESI pos.) m/z : 249 [M+H]+
MS (ESI pos.) m/z : 221 [M+H]+
MS (ESI pos.) m/z : 428 [M+Na]+
MS (ESI pos.) m/z : 303 [M+H]+
MS (ESI pos.) m/z : 345 [M+H]+
MS (ESI pos.) m/z : 317 [M+H]+
MS (ESI pos.) m/z :475 [M+Na]+
MS (ESI pos.) m/z : 322 [M+H]+
MS (ESI pos.) m/z : 222 [M+H]+
MS (ESI pos.) m/z : 407 [M+H]+
MS (ESI pos.) m/z : 350 [M+H]+
MS (ESI pos.) m/z : 250 [M+H]+
1H NMR (600 MHz, CHLOROFORM-d) δ ppm : 1.04 - 1.27 (m, 3 H), 1.44 (s, 9 H), 3.14 - 3.50 (m, 2 H), 3.84 (br. s., 1 H), 4.53 (br. s., 1 H)
MS (ESI pos.) m/z : 321 [M+H]+
MS (ESI pos.) m/z : 406 [M+H]+
MS (ESI pos.) m/z : 220 [M+H]+
MS (ESI pos.) m/z : 421 [M+H]+
MS (ESI pos.) m/z : 322 [M+H]+
MS (ESI pos.) m/z : 350 [M+H]+
MS (ESI pos.) m/z : 250 [M+H]+
MS (ESI pos.) m/z : 166 [M+H]+
MS (ESI pos.) m/z : 345 [M+Na]+
MS (ESI pos.) m/z : 373 [M+Na]+
MS (ESI pos.) m/z : 251 [M+H]+
MS (ESI pos.) m/z : 349 [M+H]+
MS (ESI pos.) m/z : 249 [M+H]+
MS (ESI pos.) m/z : 206 [M+H]+
MS (ESI pos.) m/z : 250 [M+H]+
1H NMR (200 MHz, CHLOROFORM-d) δ ppm 1.07 (d, J=6.15 Hz, 3 H) 3.01 - 3.54 (m, 6 H) 4.65 (s, 2 H)
MS (ESI pos.) m/z : 305 [M+H]+
MS (ESI pos.) m/z : 333 [M+H]+
MS (ESI pos.) m/z : 302[M+Na]+
MS (ESI pos.) m/z : 330[M+Na]+
参考例103 安息香酸 (2S)-2-(エチルアミノ)プロピル
MS (ESI pos.) m/z : 208[M+H]+
MS (ESI pos.) m/z : 393 [M+H]+
MS (ESI pos.) m/z : 289 [M+H]+
表題化合物は以下の様にして得ることもできる。
参考例104で得られた安息香酸 (2S)-2-{エチル[5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンゾイル]アミノ}プロピル(0.40g、1.02mmol)と3M KOH水溶液(0.51mL、1.53mmol)のMeOH溶液(4mL)を室温で12時間撹拌した。反応液にEtOAcを加え、飽和NaHCO3水溶液、水、brineで洗浄後、減圧下溶媒を留去した。得られた残渣をカラムクロマトグラフィー(Grace NH 12g、hexane/EtOAc=84/16~0/100)で精製することにより、表題化合物(0.29g)を得た(無色油状物)。
また、表題化合物は以下の様にして得ることもできる。
(2S)-2-(エチルアミノ)プロパン-1-オール(0.14g、1.35mmol)と5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)安息香酸(0.25g、1.23mmol)を原料にして、参考例10と同様の手法により、表題化合物(0.31g)を得た(無色油状物)。
MS (ESI pos.) m/z : 314 [M+H]+
MS (ESI pos.) m/z : 307 [M+H]+
MS (ESI pos.) m/z : 298 [M+H]+
MS (ESI pos.) m/z : 102 [M+H]+
MS (ESI pos.) m/z : 104 [M+H]+
LCMS retention time 5.07 min.
MS (ESI pos.) m/z : 434 [M+H]+
LCMS retention time 4.82 min.
MS (ESI pos.) m/z : 420 [M+H]+
LCMS retention time 0.94 min.
MS (ESI pos.) m/z : 449 [M+H]+
LCMS retention time 0.758 min.
MS (ESI pos.) m/z : 450 [M+H]+
LCMS retention time 0.841, 0.925 min.
MS (ESI pos.) m/z : 422 [M+H]+
表題化合物は以下の様にして得ることもできる。
参考例108で得られたN-[(2S)-1-シアノプロパン-2-イル]-N-エチル-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド(0.099g、0.33mmol)と5-フルオロピリジン-2-カルボン酸(0.064g、0.36mmol)を原料にして、参考例45と同様の手法により、表題化合物(0.070g)を得た(無色油状物)。
LCMS retention time 0.710 min.
MS (ESI pos.) m/z : 435 [M+H]+
LCMS retention time 0.914 min.
MS (ESI pos.) m/z : 451 [M+H]+
LCMS retention time 0.500, 0.545 min.
MS (ESI pos.) m/z : 436 [M+H]+
LCMS retention time 0.989 min.
MS (ESI pos.) m/z : 434 [M+H]+
LCMS retention time 0.823 min.
MS (ESI pos.) m/z : 450 [M+H]+
LCMS retention time 1.173 min.
MS (ESI pos.) m/z : 434 [M+H]+
LCMS retention time 1.059 min.
MS (ESI pos.) m/z : 435 [M+H]+
LCMS retention time 0.374, 0.438 min.
MS (ESI pos.) m/z : 436 [M+H]+
LCMS retention time 0.556 min.
MS (ESI pos.) m/z : 436 [M+H]+
LCMS retention time 1.064 min.
MS (ESI pos.) m/z : 450 [M+H]+
LCMS retention time 0.784 min.
MS (ESI pos.) m/z : 432 [M+H]+
LCMS retention time 0.964 min.
MS (ESI pos.) m/z : 446 [M+H]+
LCMS retention time 0.981 min.
MS (ESI pos.) m/z : 463 [M+H]+
試験化合物のヒトオレキシン1型受容体(hOX1R)、オレキシン2型受容体(hOX2R)に対する拮抗活性は文献(Toshikatsu Okumura et al., Biochemical and Biophysical Research Communications, 280, 976-981, 2001)に記載された方法を改変して行った。hOX1R、hOX2Rを強制発現させたChinese hamster ovary(CHO)細胞を96wellのBlack clear bottomプレート(Nunc)の各ウェルに20,000個となるように播種し、0.1mM MEM非必須アミノ酸、0.5mg/mL G418、10% 牛胎児血清を含むHam’s F-12培地(以上インビトロジェン)で、37℃、5% CO2の条件下で16時間培養した。培地を除去後、0.5μM Fluo-4AM エステル(同仁)を含むアッセイ用緩衝液(25mM HEPES(同仁)、Hanks’ balanced salt solution(インビトロジェン)、0.1% 牛血清アルブミン、2.5mM プロベネシド、200μg/mL Amaranth(以上Sigma-Aldrich)、pH7.4)を100μL添加し60分間、37℃、5% CO2にインキュベートした。Fluo-4AM エステルを含むアッセイ用緩衝液を除去したのち、試験化合物は10mMとなるようにジメチルスルホキシドで溶解してアッセイ用緩衝液で希釈後、150μLを添加し、30分間インキュベートした。
本発明化合物のIC50値を表15に示す。
Claims (25)
- 式(Ia)
X1及びX2は、同一に又は異なって窒素原子、又は式CHを示し、
Yは下記式群(a)のいずれかの構造を示し、
R2は、C1-6アルキル基(該C1-6アルキル基は、水酸基、C1-6アルコキシ基、C1-6アルキルスルホニル基、ジC1-6アルキルアミノ基、及びシアノ基からなる群より選ばれる1個の置換基で置換されてもよい)を示し、
R3は、トリアゾリル基、又はピリミジニル基を示し、
R4及びR5は、同一又は異なって水素原子、ハロゲン原子、C1-6アルキル基、水酸基、又はC1-6アルコキシ基を示し、
R6は、C1-6アルキル基を示す)
で表される化合物、又はその医薬上許容される塩。 - 上記式(Ia)において、
R1が、水素原子、フッ素原子、又はメチル基である請求項1~3のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 上記式(Ia)において、
R2が、メチル基、又はエチル基(該エチル基は、水酸基及びメトキシ基からなる群より選ばれる1個の置換基で置換されてもよい)である請求項1~4のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 上記式(Ia)において、
R4が、フッ素原子である請求項1~5のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 上記式(Ia)において、
R5が、水素原子、又はフッ素原子である請求項1~6のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 上記式(Ia)において、
R6が、C1-3アルキル基である請求項1~7のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 上記式(Ia)において、
R2が、エチル基である請求項1~10のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 上記式(Ia)において、
R6が、メチル基である請求項1~11のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 上記式(I)において、
R1が、水素原子、フッ素原子、又はメチル基である請求項15に記載の化合物、又はその医薬上許容される塩。 - 上記式(I)において、
R2が、メチル基、又はエチル基である請求項15又は16いずれかに記載の化合物、又はその医薬上許容される塩。 - 上記式(I)において、
R4が、フッ素原子である請求項15~17のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 上記式(I)において、
R5が、水素原子、又はフッ素原子である請求項15~18のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 上記式(I)において、
R6が、C1-3アルキル基である請求項15~19のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 上記式(I)において、
R6が、メチル基である請求項15~20のいずれか1項に記載の化合物、又はその医薬上許容される塩。 - 請求項1に記載される下記化合物群及びその医薬上許容される塩から選ばれるいずれか1種又は2種以上の混合物。
N-エチル-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2R)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
5-フルオロ-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,5-ジメチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-2-フルオロ-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-(ピリミジン-2-イル)ベンズアミド、
N-エチル-4-フルオロ-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-メチル-3-(ピリミジン-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[3-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[3-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-5-フルオロ-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]ブタン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,6-ジメチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N,6-ジメチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-エチル-5-フルオロ-2-(ピリミジン-2-イル)ベンズアミド、
5-フルオロ-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[4-(3,4-ジフルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-フルオロ-N-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
5-クロロ-N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[3-(5-フルオロピリジン-2-イル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-6-メチル-3-(ピリミジン-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-N,5-ジメチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-N-(2-メトキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-6-メチル-3-(ピリミジン-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(4-フルオロフェニル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシエチル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{1-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-4-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{1-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(4-フルオロフェニル)-1,3,4-オキサジアゾール-2-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(5-フルオロピリジン-2-イル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-6-メチル-3-(2H-1,2,3-トリアゾール-2-イル)ピリジン-2-カルボキサミド、
N-エチル-5-フルオロ-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-2H-テトラゾール-2-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[5-(5-フルオロピリジン-2-イル)-2H-テトラゾール-2-イル]プロパン-2-イル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-[2-(ジメチルアミノ)エチル]-N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-N-[2-(メチルスルホニル)エチル]-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-クロロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-N-エチル-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(3-ヒドロキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-メチル-N-{(2S)-1-[4-(ピリジン-2-イル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-メチル-N-[(2S)-1-(4-フェニル-1H-1,2,3-トリアゾール-1-イル)プロパン-2-イル]-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-メチル-N-{(2S)-1-[4-(3-メチルフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(3-フルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-フルオロ-3-メトキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(4-ヒドロキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{(2S)-1-[4-(3-メトキシフェニル)-1H-1,2,3-トリアゾール-1-イル]プロパン-2-イル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{(2S)-1-[4-(4-フルオロフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル}-N-(2-ヒドロキシプロピル)-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド。 - 請求項1~23いずれか1項に記載の化合物、又はその医薬上許容される塩を有効成分として含有する医薬組成物。
- 請求項1~23いずれか1項に記載の化合物、又はその医薬上許容される塩を有効成分として含有する睡眠障害、うつ病、不安障害、パニック障害、統合失調症、薬物依存症、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、摂食障害、頭痛、片頭痛、疼痛、消化器疾患、てんかん、炎症、免疫関連疾患、内分泌関連疾患、又は高血圧の疾患の治療又は予防薬。
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13804194.2A EP2862855A4 (en) | 2012-06-15 | 2013-06-13 | HETERO-AROMATIC ALKYL RING DERIVATIVE WITH BRANCHED CHAINS |
CA2876249A CA2876249A1 (en) | 2012-06-15 | 2013-06-13 | Branched chain alkyl heteroaromatic ring derivative |
AU2013275209A AU2013275209A1 (en) | 2012-06-15 | 2013-06-13 | Branched chain alkyl heteroaromatic ring derivative |
CN201380031392.1A CN104364238A (zh) | 2012-06-15 | 2013-06-13 | 支链烷基杂芳环衍生物 |
NZ702635A NZ702635A (en) | 2012-06-15 | 2013-06-13 | Branched chain alkyl heteroaromatic ring derivative |
SG11201408316SA SG11201408316SA (en) | 2012-06-15 | 2013-06-13 | Branched chain alkyl heteroaromatic ring derivative |
MX2014015298A MX2014015298A (es) | 2012-06-15 | 2013-06-13 | Derivado de anillo heteroaromatico de alquilo de cadena ramificada. |
KR20147035123A KR20150023390A (ko) | 2012-06-15 | 2013-06-13 | 분지쇄 알킬 헤테로 방향환 유도체 |
IN10489DEN2014 IN2014DN10489A (ja) | 2012-06-15 | 2013-06-13 | |
RU2015101115A RU2015101115A (ru) | 2012-06-15 | 2013-06-13 | Гетероароматическое циклическое производное с алкильной разветвленной цепью |
US14/407,326 US20150166523A1 (en) | 2012-06-15 | 2013-06-13 | Branched chain alkyl heteroaromatic ring derivative |
BR112014031109A BR112014031109A2 (pt) | 2012-06-15 | 2013-06-13 | derivado de anel heteroaromático de alquila de cadeia ramificada |
JP2014521400A JPWO2013187466A1 (ja) | 2012-06-15 | 2013-06-13 | 分岐鎖アルキルヘテロ芳香環誘導体 |
IL236139A IL236139A0 (en) | 2012-06-15 | 2014-12-08 | Heteroaromatic ring derivatives with branched alkyls |
PH12014502751A PH12014502751A1 (en) | 2012-06-15 | 2014-12-09 | Branched chain alkyl heteroaromatic ring derivative |
ZA2014/09167A ZA201409167B (en) | 2012-06-15 | 2014-12-12 | Branched chain alkyl heteroaromatic ring derivative |
HK15103741.9A HK1203197A1 (en) | 2012-06-15 | 2015-04-17 | Branched chain alkyl heteroaromatic ring derivative |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012135278 | 2012-06-15 | ||
JP2012-135278 | 2012-06-15 | ||
JP2012246834 | 2012-11-09 | ||
JP2012-246834 | 2012-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013187466A1 true WO2013187466A1 (ja) | 2013-12-19 |
Family
ID=49758284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/066314 WO2013187466A1 (ja) | 2012-06-15 | 2013-06-13 | 分岐鎖アルキルヘテロ芳香環誘導体 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20150166523A1 (ja) |
EP (1) | EP2862855A4 (ja) |
JP (1) | JPWO2013187466A1 (ja) |
KR (1) | KR20150023390A (ja) |
CN (1) | CN104364238A (ja) |
AU (1) | AU2013275209A1 (ja) |
BR (1) | BR112014031109A2 (ja) |
CA (1) | CA2876249A1 (ja) |
HK (1) | HK1203197A1 (ja) |
IL (1) | IL236139A0 (ja) |
IN (1) | IN2014DN10489A (ja) |
MX (1) | MX2014015298A (ja) |
NZ (1) | NZ702635A (ja) |
PH (1) | PH12014502751A1 (ja) |
RU (1) | RU2015101115A (ja) |
SG (1) | SG11201408316SA (ja) |
TW (1) | TW201412723A (ja) |
WO (1) | WO2013187466A1 (ja) |
ZA (1) | ZA201409167B (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017057717A1 (ja) * | 2015-10-02 | 2017-04-06 | 大正製薬株式会社 | 複素芳香環誘導体 |
WO2017178340A1 (en) | 2016-04-15 | 2017-10-19 | Boehringer Ingelheim International Gmbh | Novel n-[(pyridyloxy)propanyl]benzamides |
WO2017178339A1 (en) | 2016-04-15 | 2017-10-19 | Boehringer Ingelheim International Gmbh | Novel n-[(pyrazinyloxy)propanyl]benzamides |
WO2017178338A1 (en) | 2016-04-15 | 2017-10-19 | Boehringer Ingelheim International Gmbh | Novel n-[(pyrimidinyloxy)propanyl]benzamides |
JP2019503390A (ja) * | 2016-01-29 | 2019-02-07 | シー4エックス・ディスカヴァリー・リミテッド | 治療用化合物 |
WO2019025275A1 (en) | 2017-07-31 | 2019-02-07 | Boehringer Ingelheim International Gmbh | NOVEL N - [(PYRIMIDINYLAMINO) PROPANYL] -, N - [(PYRIDYLAMINO) PROPANYL] - AND N - [(PYRAZINYLAMINO) PROPANYL] ARYLCARBOXAMIDES |
WO2019063605A1 (en) | 2017-09-28 | 2019-04-04 | Boehringer Ingelheim International Gmbh | NOVEL N- (2,2-DIFLUOROETHYL) -N - [(PYRIMIDINYLAMINO) PROPANYL] ARYLCARBOXAMIDES |
JP2019511546A (ja) * | 2016-04-15 | 2019-04-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なn−[(ピリミジニルアミノ)プロパニル]−およびn−[(ピリジニルアミノ)プロパニル]アリールカルボキサミド |
US11059828B2 (en) | 2009-10-23 | 2021-07-13 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators |
US11241432B2 (en) | 2016-03-10 | 2022-02-08 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106243052B (zh) * | 2015-06-09 | 2020-01-21 | 广东东阳光药业有限公司 | 取代的杂环化合物及其制备方法和用途 |
AU2016295693B2 (en) | 2015-07-17 | 2020-05-21 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
WO2017178341A1 (en) * | 2016-04-15 | 2017-10-19 | Boehringer Ingelheim International Gmbh | Novel n-[(pyrimidinylamino)propanyl]-and n [(pyrazinylamino)propanyl]arylcarboxamides |
EP3442965B1 (en) * | 2016-04-15 | 2021-05-26 | Boehringer Ingelheim International GmbH | Novel n-[(heteroaryloxy)propanyl]heteroaryl carboxamides |
CN106674207B (zh) * | 2016-12-09 | 2019-04-19 | 广东东阳光药业有限公司 | 取代的芳基杂芳基化合物及其用途 |
CN111909044A (zh) * | 2019-05-09 | 2020-11-10 | 南京爱德程医药科技有限公司 | 2-(烷基氨基)乙基苯甲酸酯类化合物的合成方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003002559A2 (en) | 2001-06-28 | 2003-01-09 | Smithkline Beecham P.L.C. | Piperidine compounds for use as orexin receptor antagonist |
WO2008062878A1 (fr) | 2006-11-22 | 2008-05-29 | Nihon Nohyaku Co., Ltd. | Nouveau dérivé de pyrazole, agent de lutte contre des organismes nuisibles et utilisation de l'agent de lutte contre des organismes nuisibles |
JP2010520206A (ja) * | 2007-03-02 | 2010-06-10 | メルク・シャープ・エンド・ドーム・コーポレイション | ビピリジンカルボキサミドオレキシン受容体アンタゴニスト |
JP2010535769A (ja) * | 2007-08-09 | 2010-11-25 | メルク・シャープ・エンド・ドーム・コーポレイション | ピリジンカルボキサミドオレキシン受容体アンタゴニスト |
WO2011051540A1 (en) | 2009-10-27 | 2011-05-05 | Orion Corporation | Androgen receptor modulating compounds |
JP2012505263A (ja) * | 2008-10-14 | 2012-03-01 | アクテリオン ファーマシューティカルズ リミテッド | フェネチルアミド誘導体及びそれらのヘテロシクリル類似体 |
JP2012506376A (ja) * | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換モルホリンオレキシン受容体アンタゴニスト |
JP2012507538A (ja) * | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | イソニコチンアミドオレキシン受容体アンタゴニスト |
JP2012507539A (ja) * | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト |
WO2012081692A1 (ja) * | 2010-12-17 | 2012-06-21 | 大正製薬株式会社 | ピラゾール誘導体 |
WO2012153729A1 (ja) * | 2011-05-10 | 2012-11-15 | 大正製薬株式会社 | ヘテロ芳香環誘導体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006522164A (ja) * | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−5のジアリール置換ピラゾール修飾因子 |
JP2015131802A (ja) * | 2013-12-13 | 2015-07-23 | 大正製薬株式会社 | 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬 |
-
2013
- 2013-06-13 AU AU2013275209A patent/AU2013275209A1/en not_active Abandoned
- 2013-06-13 US US14/407,326 patent/US20150166523A1/en not_active Abandoned
- 2013-06-13 JP JP2014521400A patent/JPWO2013187466A1/ja not_active Withdrawn
- 2013-06-13 BR BR112014031109A patent/BR112014031109A2/pt not_active IP Right Cessation
- 2013-06-13 WO PCT/JP2013/066314 patent/WO2013187466A1/ja active Application Filing
- 2013-06-13 EP EP13804194.2A patent/EP2862855A4/en not_active Withdrawn
- 2013-06-13 NZ NZ702635A patent/NZ702635A/en not_active IP Right Cessation
- 2013-06-13 CA CA2876249A patent/CA2876249A1/en not_active Abandoned
- 2013-06-13 CN CN201380031392.1A patent/CN104364238A/zh active Pending
- 2013-06-13 RU RU2015101115A patent/RU2015101115A/ru not_active Application Discontinuation
- 2013-06-13 SG SG11201408316SA patent/SG11201408316SA/en unknown
- 2013-06-13 IN IN10489DEN2014 patent/IN2014DN10489A/en unknown
- 2013-06-13 KR KR20147035123A patent/KR20150023390A/ko not_active Application Discontinuation
- 2013-06-13 MX MX2014015298A patent/MX2014015298A/es unknown
- 2013-06-14 TW TW102121129A patent/TW201412723A/zh unknown
-
2014
- 2014-12-08 IL IL236139A patent/IL236139A0/en unknown
- 2014-12-09 PH PH12014502751A patent/PH12014502751A1/en unknown
- 2014-12-12 ZA ZA2014/09167A patent/ZA201409167B/en unknown
-
2015
- 2015-04-17 HK HK15103741.9A patent/HK1203197A1/xx unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003002559A2 (en) | 2001-06-28 | 2003-01-09 | Smithkline Beecham P.L.C. | Piperidine compounds for use as orexin receptor antagonist |
WO2008062878A1 (fr) | 2006-11-22 | 2008-05-29 | Nihon Nohyaku Co., Ltd. | Nouveau dérivé de pyrazole, agent de lutte contre des organismes nuisibles et utilisation de l'agent de lutte contre des organismes nuisibles |
JP2010520206A (ja) * | 2007-03-02 | 2010-06-10 | メルク・シャープ・エンド・ドーム・コーポレイション | ビピリジンカルボキサミドオレキシン受容体アンタゴニスト |
JP2010535769A (ja) * | 2007-08-09 | 2010-11-25 | メルク・シャープ・エンド・ドーム・コーポレイション | ピリジンカルボキサミドオレキシン受容体アンタゴニスト |
JP2012505263A (ja) * | 2008-10-14 | 2012-03-01 | アクテリオン ファーマシューティカルズ リミテッド | フェネチルアミド誘導体及びそれらのヘテロシクリル類似体 |
JP2012506376A (ja) * | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換モルホリンオレキシン受容体アンタゴニスト |
JP2012507538A (ja) * | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | イソニコチンアミドオレキシン受容体アンタゴニスト |
JP2012507539A (ja) * | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト |
WO2011051540A1 (en) | 2009-10-27 | 2011-05-05 | Orion Corporation | Androgen receptor modulating compounds |
WO2012081692A1 (ja) * | 2010-12-17 | 2012-06-21 | 大正製薬株式会社 | ピラゾール誘導体 |
WO2012153729A1 (ja) * | 2011-05-10 | 2012-11-15 | 大正製薬株式会社 | ヘテロ芳香環誘導体 |
Non-Patent Citations (19)
Title |
---|
"The Japanese Pharmacopoeia" |
BRISBARE-ROCH C ET AL., NAT. MED., vol. 13, 2007, pages 150 - 155 |
COX CD ET AL., J. MED. CHEM., vol. 53, 2010, pages 5320 - 5332 |
HAGAN JJ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 10911 - 10916 |
J. F. W. MCOMIE, PROTECTIVE GROUPS IN ORGANIC CHEMISTRY |
J. F.W. MCOMIE, PROTECTIVE GROUPS IN ORGANIC CHEMISTRY |
JOHN G ET AL., CHEMMEDCHEM., vol. 5, 2010, pages 1197 - 1214 |
JOHN GATFIELD ET AL.: "Orexin Receptor Antagonists: A New Concept In CNS Disorders", CHEMMEDCHEM, vol. 5, 2010, pages 1197 - 1214, XP009145815 * |
MARCUS JN ET AL., J. COMP. NEUROL., vol. 435, 2001, pages 6 - 25 |
NAKAMURA T ET AL., BRAIN RES., vol. 873, 2000, pages 181 - 187 |
See also references of EP2862855A4 |
SMITH MI ET AL., NEUROSCI. LETT., vol. 341, 2003, pages 256 - 258 |
SYNLETT, vol. 15, 2003, pages 2428 - 2439 |
T. W. GREENE; P. G. M. WUTS, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS |
TOSHIKATSU OKUMURA ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 280, 2001, pages 976 - 981 |
TRIVEDI JP ET AL., FEBS LETT., vol. 438, 1998, pages 71 - 75 |
YAMANAKA A ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 290, 2002, pages 1237 - 1245 |
ZEITZER JM ET AL., TRENDS PHARMACOL. SCI., vol. 27, 2006, pages 368 - 374 |
ZHU Y ET AL., J. PHARMACOL. SCI., vol. 92, 2003, pages 259 - 266 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11059828B2 (en) | 2009-10-23 | 2021-07-13 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators |
US11667644B2 (en) | 2009-10-23 | 2023-06-06 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
USRE48841E1 (en) | 2009-10-23 | 2021-12-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
WO2017057717A1 (ja) * | 2015-10-02 | 2017-04-06 | 大正製薬株式会社 | 複素芳香環誘導体 |
JP2019503390A (ja) * | 2016-01-29 | 2019-02-07 | シー4エックス・ディスカヴァリー・リミテッド | 治療用化合物 |
US11241432B2 (en) | 2016-03-10 | 2022-02-08 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
WO2017178338A1 (en) | 2016-04-15 | 2017-10-19 | Boehringer Ingelheim International Gmbh | Novel n-[(pyrimidinyloxy)propanyl]benzamides |
JP2019511546A (ja) * | 2016-04-15 | 2019-04-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なn−[(ピリミジニルアミノ)プロパニル]−およびn−[(ピリジニルアミノ)プロパニル]アリールカルボキサミド |
WO2017178339A1 (en) | 2016-04-15 | 2017-10-19 | Boehringer Ingelheim International Gmbh | Novel n-[(pyrazinyloxy)propanyl]benzamides |
WO2017178340A1 (en) | 2016-04-15 | 2017-10-19 | Boehringer Ingelheim International Gmbh | Novel n-[(pyridyloxy)propanyl]benzamides |
WO2019025275A1 (en) | 2017-07-31 | 2019-02-07 | Boehringer Ingelheim International Gmbh | NOVEL N - [(PYRIMIDINYLAMINO) PROPANYL] -, N - [(PYRIDYLAMINO) PROPANYL] - AND N - [(PYRAZINYLAMINO) PROPANYL] ARYLCARBOXAMIDES |
WO2019063605A1 (en) | 2017-09-28 | 2019-04-04 | Boehringer Ingelheim International Gmbh | NOVEL N- (2,2-DIFLUOROETHYL) -N - [(PYRIMIDINYLAMINO) PROPANYL] ARYLCARBOXAMIDES |
US11324724B2 (en) | 2017-09-28 | 2022-05-10 | Boehringer Ingelheim International Gmbh | N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides |
Also Published As
Publication number | Publication date |
---|---|
RU2015101115A (ru) | 2016-08-10 |
ZA201409167B (en) | 2016-03-30 |
US20150166523A1 (en) | 2015-06-18 |
IN2014DN10489A (ja) | 2015-08-21 |
TW201412723A (zh) | 2014-04-01 |
IL236139A0 (en) | 2015-02-01 |
CN104364238A (zh) | 2015-02-18 |
JPWO2013187466A1 (ja) | 2016-02-08 |
EP2862855A1 (en) | 2015-04-22 |
MX2014015298A (es) | 2015-03-05 |
PH12014502751A1 (en) | 2015-02-09 |
BR112014031109A2 (pt) | 2017-06-27 |
SG11201408316SA (en) | 2015-03-30 |
CA2876249A1 (en) | 2013-12-19 |
EP2862855A4 (en) | 2015-11-18 |
KR20150023390A (ko) | 2015-03-05 |
HK1203197A1 (en) | 2015-10-23 |
NZ702635A (en) | 2016-11-25 |
AU2013275209A1 (en) | 2015-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013187466A1 (ja) | 分岐鎖アルキルヘテロ芳香環誘導体 | |
JP6218808B2 (ja) | Lrrk2モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体 | |
WO2012153729A1 (ja) | ヘテロ芳香環誘導体 | |
JP5896319B2 (ja) | ヘテロ芳香環メチル環状アミン誘導体 | |
WO2012081692A1 (ja) | ピラゾール誘導体 | |
WO2015152367A1 (ja) | オキソ複素環誘導体 | |
WO2013005755A1 (ja) | メチルピペリジン誘導体 | |
JP5451633B2 (ja) | トリアゾールオキサジアゾール誘導体 | |
KR20110133034A (ko) | 가용성 구아닐레이트 시클라제 활성화제 | |
JP6183451B2 (ja) | 2−アシルアミノチアゾール誘導体またはその塩 | |
JP2009536213A (ja) | 縮合複素環化合物及びmglur5モジュレーターとしてのその使用 | |
JP2014015452A (ja) | ピラゾール誘導体を含有する医薬 | |
JP2015131802A (ja) | 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬 | |
CN112055713A (zh) | 用于治疗与apj受体活性有关的疾病的化合物和组合物 | |
JP5930010B2 (ja) | ヘテロ芳香環メチル環状アミン誘導体を含有する医薬 | |
JP2014141480A (ja) | メチルピペリジン誘導体を含有する医薬 | |
WO2015087993A1 (ja) | オキサゾリジン及びオキサジナン誘導体 | |
JP2014111586A (ja) | ヘテロ芳香環誘導体を含有する医薬 | |
WO2017057717A1 (ja) | 複素芳香環誘導体 | |
TW202339720A (zh) | 作為trpa1抑制劑之噠嗪酮化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13804194 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014521400 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2876249 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14407326 Country of ref document: US Ref document number: MX/A/2014/015298 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20147035123 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013804194 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013804194 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015101115 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013275209 Country of ref document: AU Date of ref document: 20130613 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014031109 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014031109 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141211 |